celecoxib has been researched along with Disease Models, Animal in 339 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a phase II clinical trial, we sought to determine if combining celecoxib with 13-cis-retinoic acid (13-cRA, Accutane) was efficacious in the treatment of recurrent (progressive) glioblastoma multiforme (GBM)." | 9.12 | Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. ( Giglio, P; Groves, MD; Hess, K; Jochec, J; Levin, VA; Puduvalli, VK; Yung, WK, 2006) |
| "This study aims to investigate the effects of the cyclooxygenase-2 (COX-2) inhibitor celecoxib on neonatal necrotizing enterocolitis (NEC) in rats." | 8.02 | Low-dose cyclooxygenase-2 (COX-2) inhibitor celecoxib plays a protective role in the rat model of neonatal necrotizing enterocolitis. ( Sun, L, 2021) |
| "Liver cirrhosis was induced by thioacetamide (TAA)." | 8.02 | Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats. ( Gan, C; Gao, J; Huang, Z; Jia, X; Jiang, J; Liu, R; Ma, X; Su, W; Tai, Y; Tang, C; Tang, S; Wu, H; Ye, Y; Zhang, L; Zhao, C, 2021) |
| " The present study evaluated the effect of oral administration of five days celecoxib regimen (20 mg/kg/day) against different developmental stages of Schistosoma mansoni infection." | 8.02 | Effect of celecoxib against different developmental stages of experimental Schistosoma mansoni infection. ( Abou-El-Naga, IF; El-Temsahy, MM; Ibrahim, EI; Makled, S; Mogahed, NMFH; Sheta, E, 2021) |
| "To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS)." | 7.96 | Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. ( Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM, 2020) |
| "BACKGROUND Literature shows that serum selenium concentration is low in rheumatoid arthritis (RA) patients." | 7.91 | Selenium Nanoparticles Dispersed in Phytochemical Exert Anti-Inflammatory Activity by Modulating Catalase, GPx1, and COX-2 Gene Expression in a Rheumatoid Arthritis Rat Model. ( Lin, Y; Ma, DS; Ren, SX; Yan, H; Zhan, B, 2019) |
| "We evaluated the effect of the co-administration of fluoxetine (5 mg/kg) and flurbiprofen (5 mg/kg) or fluoxetine (5 mg/kg) and celecoxib (5 mg/kg) in the chronic escape deficit (CED) model of depression after 7 days of treatment." | 7.88 | Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression. ( Alboni, S; Benatti, C; Brunello, N; Capone, G; Tascedda, F, 2018) |
| " In the present study, we report the nanoconjugates of mercaptopropionic acid- (MPA-) capped CdTe quantum dots (QDs) and Celecoxib for bio-imaging in carrageenan-induced mouse paw edema model of inflammation." | 7.88 | Synthesis, Characterization, and Biodistribution of Quantum Dot-Celecoxib Conjugate in Mouse Paw Edema Model. ( Jain, S; Kalangi, SK; Narayana Rao, D; Reddanna, P; Sathyavathi, R; Swarnakar, NK, 2018) |
| " Celecoxib and plumbagin are two drugs that were identified from a screen to synergistically kill melanoma cells compared with normal cells." | 7.85 | Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. ( Gowda, R; Kardos, G; Robertson, GP; Sharma, A; Singh, S, 2017) |
| "Celecoxib cardiotoxicity was manifested by significant increases in the LDH, Tn-T, TNF-α, CK-MB, SBP, HR (p < 0." | 7.85 | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. ( Ahmad, S; Dubey, K; Fahim, M; Kohli, K; Panda, BP, 2017) |
| " Dacarbazine (DTIC) is one of the most commonly used drugs in the treatment of metastatic melanoma." | 7.83 | In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine. ( Averineni, RK; Guan, X; Sadhu, SS; Seefeldt, T; Wang, S; Yang, Y, 2016) |
| "The aim of this study is to clarify the following two points: First, whether a cyclooxygenase-2 mediated pathway is involved in the formation of immobilization-induced joint contracture and, second, the effectiveness of oral administration of non-steroidal anti-inflammatory drug celecoxib (CBX) for the prevention of myogenic and arthrogenic contracture following immobilization in a rat model." | 7.83 | Cyclooxygenase-2 inhibitor celecoxib attenuates joint contracture following immobilization in rat knees. ( Kaneguchi, A; Kito, N; Moriyama, H; Ozawa, J; Tanaka, R, 2016) |
| " The objective of the present study was to examine whether celecoxib, a selective COX-2 inhibitor, can reduce systemic LPS-induced brain inflammation and brain damage." | 7.79 | Celecoxib attenuates systemic lipopolysaccharide-induced brain inflammation and white matter injury in the neonatal rats. ( Bhatt, AJ; Cai, Z; Fan, LW; Kaizaki, A; Numazawa, S; Pang, Y; Tanaka, S; Tien, LT, 2013) |
| "To study the feasibility of chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2(COX-2) inhibitor using a rat model." | 7.78 | [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor]. ( Lang, HJ; Liang, XH; Su, LW; Wang, YJ; Zhang, F; Zhang, T; Zhou, YA; Zhu, YF, 2012) |
| "To evaluate the effects of celecoxib and rosiglitazone on the implantation and growth of endometriotic-like lesions in a murine model of endometriosis." | 7.77 | The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. ( Barañao, RI; Bilotas, M; Meresman, G; Olivares, C; Ricci, A, 2011) |
| "To test the efficacy of an animal model of pain and stress and evaluate the effects of celecoxib administered when orthodontic force is applied." | 7.75 | Effect of celecoxib on emotional stress and pain-related behaviors evoked by experimental tooth movement in the rat. ( Gonzales, C; Hotokezaka, H; Koga, Y; Shibazaki, T; Yoshida, N; Yozgatian, JH; Zeredo, JL, 2009) |
| "The COX-2 inhibitor celecoxib decreased neuronal excitability and prevented epileptogenesis in pilocarpine-induced status epilepticus rats." | 7.74 | Cyclooxygenase-2 inhibitor inhibits hippocampal synaptic reorganization in pilocarpine-induced status epilepticus rats. ( Lei, GF; Liu, CX; Sun, RP; Yang, L; Zhang, HJ, 2008) |
| "Memantine, a N-methyl-D-aspartate (NMDA) receptor antagonist, inhibits hematoma expansion and celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces perihematomal inflammation in intracerebral hemorrhage." | 7.74 | Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. ( Chu, K; Jung, KH; Kim, JM; Kim, M; Lee, ST; Park, DK; Roh, JK; Sinn, DI; Song, EC, 2007) |
| "The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia." | 7.74 | Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. ( Kita, Y; Murata, Y; Okumura, T; Sakakibara, A, 2008) |
| " To clarify the role of COX-2 in atherosclerosis, we conducted a study to test whether the COX-2 inhibitor, celecoxib, prevents the development and progression of the atherosclerotic process." | 7.74 | The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice. ( Jacob, S; Lanza-Jacoby, S; Laury-Kleintop, L, 2008) |
| "Growth inhibitory effects of celecoxib were evaluated in Y79 and Weri-RB1 human retinoblastoma cell lines by WST-1 cell proliferation assay." | 7.73 | Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. ( Grossniklaus, HE; Howard, SA; Lin, ET; O'Brien, JM; Shah, HR; Tong, CT; Van Quill, KR, 2005) |
| "To investigate the action of celecoxib (a selective COX-2 inhibitor) in a rat model of colitis induced by trinitrobenzene sulfonic acid (TNBS)." | 7.72 | Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. ( Dong, XY; Lu, YM; Zhang, L, 2004) |
| " In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer." | 7.70 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. ( Grubbs, CJ; Hill, DL; Kelloff, GJ; Koki, AT; Leahy, KM; Lubet, RA; Masferrer, JL; Seibert, K; Steele, VE, 2000) |
| "Intervertebral disc degeneration (IDD) has been identified as one of the predominant factors leading to persistent low back pain and disability in middle-aged and elderly people." | 5.91 | Low-dose celecoxib-loaded PCL fibers reverse intervertebral disc degeneration by up-regulating CHSY3 expression. ( Cao, P; Chen, H; Hu, B; Li, J; Liang, L; Wang, J; Wang, Y; Wei, L; Wu, J; Wu, X; Xiao, Q; Xie, X; Xu, C; Yang, C; Yu, W; Zang, F; Zhang, R; Zhang, T; Zheng, G, 2023) |
| "Metformin was administered orally every day to rats with OA." | 5.62 | Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021) |
| "Depression was induced by IFNα (16 × 105 IU/kg, SC) for six consecutive days." | 5.51 | Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice. ( Hajhashemi, V; Mesripour, A; Shahnooshi, S, 2019) |
| "Kartogenin (KGN) is a small drug-like molecule that induces chondrogenesis in mesenchymal stem cells (MSCs)." | 5.48 | Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10. ( Cho, KH; Cho, ML; Choi, J; Jung, K; Kim, SJ; Kwon, JY; Lee, CY; Lee, SH; Na, HS; Park, SH; Shin, DY, 2018) |
| "Celecoxib treatment led to decreased PGE2 and corticosterone levels, reduced proliferation and increased apoptosis of adrenocortical cells, and decreased steroidogenic gene expression." | 5.43 | Celecoxib reduces glucocorticoids in vitro and in a mouse model with adrenocortical hyperplasia. ( Berthon, A; Faucz, FR; Liu, S; Martinez, A; Sahut-Barnola, I; Saloustros, E; Salpea, P; Starost, MF; Stratakis, CA; Szarek, E, 2016) |
| "The prognosis of muscle-invasive bladder cancer with metastasis is poor." | 5.43 | A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells. ( Aono, Y; Horinaka, M; Miki, T; Morioka, Y; Sakai, T; Takamura, T; Taniguchi, T; Toriyama, S; Ukimura, O; Yasuda, S, 2016) |
| "Celecoxib and citrate have been shown to possess antitumor activity in a variety of cancer cells." | 5.42 | Citrate and celecoxib induce apoptosis and decrease necrosis in synergistic manner in canine mammary tumor cells. ( Farsinejad, A; Panahi, N; Safi, S; Vahidi, R, 2015) |
| "Pain is the most common complaint in the medical field and the identification of novel compounds that can effectively treat painful states without causing side effects remains a major challenge in biomedical research." | 5.40 | Antinociceptive effect of 3-(4-fluorophenyl)-5-trifluoromethyl-1H-1-tosylpyrazole. A Celecoxib structural analog in models of pathological pain. ( Bonacorso, HG; Correa, MS; Ferreira, J; Oliveira, SM; Otuki, MF; Paim, GR; Prudente, AS; Silva, CR; Wentz, AP, 2014) |
| "Celecoxib is a selective cyclooxygenase-2 (COX2) inhibitor." | 5.39 | A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation. ( Alloza, I; Chiba, A; Di Penta, A; Miyake, S; Vandenbroeck, K; Villoslada, P; Wyssenbach, A; Yamamura, T, 2013) |
| "Autosomal dominant polycystic kidney disease (ADPKD) is a progressive chronic kidney disease." | 5.38 | Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. ( Fu, LL; Mei, CL; Wang, NS; Xu, T; Ye, CY; Yu, SQ, 2012) |
| " Pharmacokinetic parameters and their between animal variability were obtained using standard non-compartmental analysis as well as a compartmental analysis using nonlinear mixed effects modeling." | 5.37 | Pharmacokinetics of a combination of Δ9-tetrahydro-cannabinol and celecoxib in a porcine model of hemorrhagic shock. ( Mehrotra, N; Meibohm, B; Moore, BM; Vaddady, PK; Yates, CR; Zhang, X, 2011) |
| "Chondrosarcomas are resistant to conventional chemo- and radiotherapy." | 5.36 | COX-2 expression in chondrosarcoma: a role for celecoxib treatment? ( Bovée, JV; Briaire-de Bruijn, I; Kalinski, T; Llombart-Bosch, A; Machado, I; Meijer, D; Schrage, YM; Taminiau, AH; van den Akker, BE, 2010) |
| "Alveolar bone loss was evaluated morphometrically under a stereomicroscope." | 5.35 | The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis. ( Atilla, G; Baylas, H; Buduneli, E; Buduneli, N; Sorsa, T; Turkoglu, O; Vardar-Sengul, S; Wahlgren, J, 2008) |
| " This may be clinically important as this dose of celecoxib can be achieved in human serum following standard anti-inflammatory dosing of 100 mg." | 5.33 | Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. ( Arber, N; Giladi, N; Kazanov, D; Lev-Ari, S; Liberman, E; Sagiv, E; Shpitz, B, 2006) |
| "Main parameter was thrombus weight." | 5.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| "This experimental, translational, experimental pain, single-center, randomized, double-blind, single-dose, 3-treatment, 3-period cross-over proof-of-concept volunteer trial studied the efficacy of a novel TRPV1 antagonist (V116517) on capsaicin- and UV-B-induced hyperalgesia." | 5.22 | A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile. ( Arendt-Nielsen, L; Harris, S; Hummel, M; Kapil, R; Knappenberger, T; Kyle, D; O'Keefe, S; Whiteside, GT, 2016) |
| "In a phase II clinical trial, we sought to determine if combining celecoxib with 13-cis-retinoic acid (13-cRA, Accutane) was efficacious in the treatment of recurrent (progressive) glioblastoma multiforme (GBM)." | 5.12 | Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. ( Giglio, P; Groves, MD; Hess, K; Jochec, J; Levin, VA; Puduvalli, VK; Yung, WK, 2006) |
| "This study aims to investigate the effects of the cyclooxygenase-2 (COX-2) inhibitor celecoxib on neonatal necrotizing enterocolitis (NEC) in rats." | 4.02 | Low-dose cyclooxygenase-2 (COX-2) inhibitor celecoxib plays a protective role in the rat model of neonatal necrotizing enterocolitis. ( Sun, L, 2021) |
| "Liver cirrhosis was induced by thioacetamide (TAA)." | 4.02 | Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats. ( Gan, C; Gao, J; Huang, Z; Jia, X; Jiang, J; Liu, R; Ma, X; Su, W; Tai, Y; Tang, C; Tang, S; Wu, H; Ye, Y; Zhang, L; Zhao, C, 2021) |
| " The present study evaluated the effect of oral administration of five days celecoxib regimen (20 mg/kg/day) against different developmental stages of Schistosoma mansoni infection." | 4.02 | Effect of celecoxib against different developmental stages of experimental Schistosoma mansoni infection. ( Abou-El-Naga, IF; El-Temsahy, MM; Ibrahim, EI; Makled, S; Mogahed, NMFH; Sheta, E, 2021) |
| " The acetylcholinesterase inhibitor (ACHEI); neostigmine, is known clinically for its analgesic effect in the perioperative phases proving high efficacy; besides possessing anti-inflammatory properties controlling immune cells and cytokine level." | 4.02 | The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation. ( Abdel-Bary, A; El-Tahan, RA; Gowayed, MA, 2021) |
| " Therefore, this study examined the effect of KML29 alone as well as in combination with low-dose celecoxib (CXB) on joint pain and inflammation in the monoiodoacetate (MIA) model of osteoarthritis (OA) pain." | 3.96 | Combatting joint pain and inflammation by dual inhibition of monoacylglycerol lipase and cyclooxygenase-2 in a rat model of osteoarthritis. ( McDougall, JJ; Philpott, HT, 2020) |
| " The purpose of this study was to use a validated rabbit model to assess the effects on surgically-induced knee joint contractures of two combined pharmacological interventions: celecoxib (CXB) loaded on an implanted collagen membrane, and subcutaneously (SQ) injected ketotifen." | 3.96 | Reduction of arthrofibrosis utilizing a collagen membrane drug-eluting scaffold with celecoxib and subcutaneous injections with ketotifen. ( Abdel, MP; Berry, CE; Berry, DJ; Bolon, B; Carter, JM; Jay, AG; Limberg, AK; McLaury, AR; Morrey, ME; Salib, CG; Sanchez-Sotelo, J; Tibbo, ME; Turner, TW; van Wijnen, AJ, 2020) |
| "To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS)." | 3.96 | Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. ( Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM, 2020) |
| "The goal of the current investigation was to prepare PEGylated Lipova E120 liposomes loaded with celecoxib for the effective treatment of rheumatoid arthritis (RA)." | 3.91 | PEGylated Lipova E120 liposomes loaded with celecoxib: ( Dave, V; Gupta, A; Sharma, S; Singh, P; Tak, K, 2019) |
| "BACKGROUND Literature shows that serum selenium concentration is low in rheumatoid arthritis (RA) patients." | 3.91 | Selenium Nanoparticles Dispersed in Phytochemical Exert Anti-Inflammatory Activity by Modulating Catalase, GPx1, and COX-2 Gene Expression in a Rheumatoid Arthritis Rat Model. ( Lin, Y; Ma, DS; Ren, SX; Yan, H; Zhan, B, 2019) |
| " The objective was to evaluate the morphological, hormonal, and inflammatory responses in the prostate anterior lobe in transgenic adenocarcinoma of the mouse prostate (TRAMP), following Celecoxib and Goniothalamin (GTN) treatments." | 3.88 | Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice. ( Cagnon, VHA; Kido, LA; Montico, F; Pilli, RA; Silva, RS; Vendramini-Costa, DB, 2018) |
| "We evaluated the effect of the co-administration of fluoxetine (5 mg/kg) and flurbiprofen (5 mg/kg) or fluoxetine (5 mg/kg) and celecoxib (5 mg/kg) in the chronic escape deficit (CED) model of depression after 7 days of treatment." | 3.88 | Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression. ( Alboni, S; Benatti, C; Brunello, N; Capone, G; Tascedda, F, 2018) |
| "Epirubicin is a chemotherapy agent for hepatocellular carcinoma (HCC)." | 3.88 | Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats. ( Chan, HH; Chang, YC; Chen, YA; Chu, TH; Hu, TH; Huang, SC; Ma, YL; Tai, MH; Wang, EM; Wen, ZH; Weng, WT; Wu, DC; Wu, JC, 2018) |
| " Pelvic pain had developed in EAP rats, which was attenuated by a single treatment with celecoxib or pregabalin, suggesting that EAP is an appropriate model for prostatitis-related pain." | 3.88 | Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: Effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain. ( Kotera, T; Kurita, M; Oka, M; Okamoto, K; Yamaguchi, H, 2018) |
| " In the present study, we report the nanoconjugates of mercaptopropionic acid- (MPA-) capped CdTe quantum dots (QDs) and Celecoxib for bio-imaging in carrageenan-induced mouse paw edema model of inflammation." | 3.88 | Synthesis, Characterization, and Biodistribution of Quantum Dot-Celecoxib Conjugate in Mouse Paw Edema Model. ( Jain, S; Kalangi, SK; Narayana Rao, D; Reddanna, P; Sathyavathi, R; Swarnakar, NK, 2018) |
| " All synthesized new compounds along with compound III as a parent compound and Celecoxib as a reference, were assessed for their antiinflammatory activity both in-vivo and in-vitro using the formalin-induced hind paw edema method and inhibition of albumin denaturation and Red Blood Cells (RBCs) membrane stabilization, respectively." | 3.88 | Synthesis, In-vivo and In-vitro Anti-inflammatory Evaluation of some Novel Coumarin Derivatives. ( Al-Wabli, R; El-Haggar, R; Fouad, M, 2018) |
| " Amongst all the synthesized derivatives, compound 56 showed the significant anti-inflammatory activity in both rat paw edema models with very less ulcerogenic liability in comparison to standard diclofenac, celecoxib, and zileuton." | 3.85 | Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity. ( Bandresh, R; Shrivastava, SK; Srivastava, P; Tripathi, A; Tripathi, PN, 2017) |
| "Intravitreal injection of celecoxib could suppress the thickness and area of laser-induced macular degeneration CNV." | 3.85 | Effects of epoxyeicosatrienoic acids (EETs) on retinal macular degeneration in rat models. ( Chen, ZJ; Mei, F; Wang, JG; Yuan, ZL, 2017) |
| " Celecoxib and plumbagin are two drugs that were identified from a screen to synergistically kill melanoma cells compared with normal cells." | 3.85 | Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. ( Gowda, R; Kardos, G; Robertson, GP; Sharma, A; Singh, S, 2017) |
| "Celecoxib has protective effects on sepsis due to its preservative effects on mesenteric perfusion, aortic function and its anti-inflammatory and antioxidative effects." | 3.85 | Celecoxib administration reduced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ injury in septic rats. ( Bariskaner, H; Goktas, MT; Iskit, AB; Kilinc, I; Ozer, EK; Ugurluoglu, C, 2017) |
| "Celecoxib cardiotoxicity was manifested by significant increases in the LDH, Tn-T, TNF-α, CK-MB, SBP, HR (p < 0." | 3.85 | Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. ( Ahmad, S; Dubey, K; Fahim, M; Kohli, K; Panda, BP, 2017) |
| "The aim of this study was to characterize the structural and molecular biology as well as evaluate the immediate and late responses of prostatic cancer in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model after treatment with goniothalamin (GTN) and celecoxib." | 3.83 | Anti-inflammatory therapies in TRAMP mice: delay in PCa progression. ( Cagnon, VH; Carvalho, JE; Costa, DB; Kido, LA; Macedo, AB; Minatel, E; Montico, F; Pilli, RA; Sauce, R, 2016) |
| " Dacarbazine (DTIC) is one of the most commonly used drugs in the treatment of metastatic melanoma." | 3.83 | In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine. ( Averineni, RK; Guan, X; Sadhu, SS; Seefeldt, T; Wang, S; Yang, Y, 2016) |
| "The aim of this study is to clarify the following two points: First, whether a cyclooxygenase-2 mediated pathway is involved in the formation of immobilization-induced joint contracture and, second, the effectiveness of oral administration of non-steroidal anti-inflammatory drug celecoxib (CBX) for the prevention of myogenic and arthrogenic contracture following immobilization in a rat model." | 3.83 | Cyclooxygenase-2 inhibitor celecoxib attenuates joint contracture following immobilization in rat knees. ( Kaneguchi, A; Kito, N; Moriyama, H; Ozawa, J; Tanaka, R, 2016) |
| " The compounds 3a, 3b, 3c, 3e, and 3f presented anti-hyperalgesic action, while the compounds 3a, 3c, 3d, 3f, and 3g exhibited anti-edematogenic effects, without causing locomotive disorders in animals, thus making them comparable to Celecoxib in an arthritic pain model." | 3.81 | Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice. ( Bonacorso, HG; Brusco, I; Canova, B; da Silva, TV; de Souza, ON; Dos Santos, JM; Lobo, MM; Machado, P; Martins, MA; Oliveira, SM; Timmers, LF; Zanatta, N, 2015) |
| "Chronic inflammation is one of the main symptoms of cancer cachexia, and cyclooxygenase 2 inhibitors, such as celecoxib, may be beneficial in counteracting the major symptoms of this syndrome." | 3.81 | Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor. ( Bi, Y; Han, M; Jiang, M; Xu, X; Zhang, Y, 2015) |
| "High-dose celecoxib (2 g/kg), a selective COX-2 inhibitor, did not cause hearing loss or tinnitus in Sprague Dawley rats within 48 hours of administration." | 3.81 | Assessment of the potential ototoxicity of high-dose celecoxib, a selective cyclooxygenase-2 inhibitor, in rats. ( Feng, Y; Li, B; Su, K; Xia, L; Yang, G; Yin, S, 2015) |
| " Here, we present a theranostic nanoemulsion platform for simultaneous delivery of an anti-inflammatory drug (celecoxib) to macrophages and monitoring of macrophage migration patterns by optical imaging, as measurement of changes in inflammation." | 3.81 | Theranostic nanoemulsions for macrophage COX-2 inhibition in a murine inflammation model. ( Anderson, CJ; Beaino, W; Janjic, JM; Patel, SK, 2015) |
| " These results suggest that ceftriaxone, particularly in combinations with ibuprofen, celecoxib, paracetamol, or levetiracetam, may provide useful approach to the clinical treatment of inflammation-related pain." | 3.80 | Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents. ( Boškovic, BD; Kovacevic, JM; Micov, AM; Stepanovic-Petrovic, RM; Tomic, MA, 2014) |
| "Several studies have shown the anti-neoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs) on 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis, but how these drugs act in case of inflammation-augmented tumorigenesis is still not clear." | 3.80 | Activation of NF-κB: bridging the gap between inflammation and cancer in colitis-mediated colon carcinogenesis. ( Nehru, B; Sanyal, SN; Setia, S, 2014) |
| " In the present study an experimental rabbit model of hypercholesterolemia was developed and the effects of COX-2 inhibitors, nimesulide and celecoxib were observed on the activities of antioxidant enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPx) and total antioxidant status (TAS)." | 3.80 | Cyclooxygenase-2 inhibition improves antioxidative defense during experimental hypercholesterolemia. ( Ahmed, S; Ercisli, S; Gul, H; Gul, S; Zia-Ul-Haq, M, 2014) |
| "Overall, this study suggested that both celecoxib and aspirin could prevent breast cancer growth by regulating proteins in the cell cycle and apoptosis without blocking estrogen synthesis." | 3.80 | Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice. ( Chan, FL; Chen, S; Leung, LK; Li, F; Lin, SM; Wong, TY, 2014) |
| " The objective of the present study was to examine whether celecoxib, a selective COX-2 inhibitor, can reduce systemic LPS-induced brain inflammation and brain damage." | 3.79 | Celecoxib attenuates systemic lipopolysaccharide-induced brain inflammation and white matter injury in the neonatal rats. ( Bhatt, AJ; Cai, Z; Fan, LW; Kaizaki, A; Numazawa, S; Pang, Y; Tanaka, S; Tien, LT, 2013) |
| "The effects of long-term use of celecoxib, ibuprofen, and indomethacin on types I, II, and III collagen metabolism were evaluated in rat osteoarthritis (OA) model." | 3.78 | The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model. ( An, H; Jiang, DM; Luo, XJ; Ou, YS; Quan, ZX; Tan, C; Tang, K, 2012) |
| "Methylmalonic acidemias are inherited metabolic disorders characterized by methylmalonate (MMA) accumulation and neurologic dysfunction, including seizures." | 3.78 | Prostaglandin E(2) potentiates methylmalonate-induced seizures. ( Banderó, CR; Bortoluzzi, VT; Bueno, LM; Gomes, AT; Jesse, AC; Mello, CF; Oliveira, MS; Rambo, LM; Salvadori, MG, 2012) |
| "To study the feasibility of chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2(COX-2) inhibitor using a rat model." | 3.78 | [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor]. ( Lang, HJ; Liang, XH; Su, LW; Wang, YJ; Zhang, F; Zhang, T; Zhou, YA; Zhu, YF, 2012) |
| "The purpose of this study was to compare the gait parameters recorded on the CatWalk and the mechanical sensitivity with von Frey filaments of two putative models of osteoarthritis over a one month period, and to evaluate the effect of celecoxib on these parameters." | 3.77 | Gait analysis and pain response of two rodent models of osteoarthritis. ( Beaudry, F; Ferland, CE; Laverty, S; Vachon, P, 2011) |
| "Celecoxib prevents lung metastasis in a murine model of Ewing sarcoma with no effect on tumor size or neovascularization." | 3.77 | Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. ( Edelman, M; Gendy, AS; Glick, RD; Lipskar, A; Soffer, SZ; Steinberg, BM, 2011) |
| "To evaluate the effects of celecoxib and rosiglitazone on the implantation and growth of endometriotic-like lesions in a murine model of endometriosis." | 3.77 | The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. ( Barañao, RI; Bilotas, M; Meresman, G; Olivares, C; Ricci, A, 2011) |
| " First, validate PEAP with Complete Freund's Adjuvant (CFA)-induced inflammation for the assessment of the affective component of pain using the reference analgesics celecoxib, diclofenac and duloxetine; fluoxetine and scopolamine were tested as negative controls." | 3.76 | Comparison of mechanical allodynia and the affective component of inflammatory pain in rats. ( Baker, SJ; Boyce-Rustay, JM; Decker, MW; Honore, P; Kohnken, R; Simler, GH; Wensink, EJ; Zhong, C, 2010) |
| ") were assessed using acetic acid-induced vascular permeability, carrageenan-induced paw edema, and croton oil-induced ear edema." | 3.76 | The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo. ( Cho, YB; Hur, J; Jung, I; Jung, KC; Kang, JY; Kang, M; Kim, KS; Kim, SH; Lee, JD; Lee, JH; Park, DS; Yoo, MC, 2010) |
| "To evaluate the effect of a cyclooxygenase 2 inhibitor, celecoxib (CEL), on bladder cancer inhibition in a rat model, when used as preventive versus as curative treatment." | 3.76 | Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model. ( Cunha, FX; Figueiredo, A; Garrido, P; Mota, A; Neto, P; Nunes, S; Parada, B; Pinto, R; Reis, F; Rocha-Pereira, P; Rodrigues-Santos, P; Ruivo, J; Sereno, J; Teixeira, F; Teixeira-Lemos, E, 2010) |
| " Additionally, LASSBio-1135 (3a) presented activity similar to celecoxib (1) regarding the reduction of the carrageenan-induced rat paw edema (33% of inhibition at 100 micromol/kg, po)." | 3.75 | Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. ( Barreiro, EJ; da Silva, LL; de Lima, CK; Fraga, CA; Lacerda, RB; Miranda, AL; Romeiro, NC, 2009) |
| "To test the efficacy of an animal model of pain and stress and evaluate the effects of celecoxib administered when orthodontic force is applied." | 3.75 | Effect of celecoxib on emotional stress and pain-related behaviors evoked by experimental tooth movement in the rat. ( Gonzales, C; Hotokezaka, H; Koga, Y; Shibazaki, T; Yoshida, N; Yozgatian, JH; Zeredo, JL, 2009) |
| "Atherosclerosis being considered as an inflammatory disorder, the present study was undertaken to investigate the effectiveness of anti-inflammatory drugs (ibuprofen, aspirin, and celecoxib) in hypercholesterolemia." | 3.74 | Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study. ( Dabhi, JK; Mehta, A; Solanki, JK, 2008) |
| "The COX-2 inhibitor celecoxib decreased neuronal excitability and prevented epileptogenesis in pilocarpine-induced status epilepticus rats." | 3.74 | Cyclooxygenase-2 inhibitor inhibits hippocampal synaptic reorganization in pilocarpine-induced status epilepticus rats. ( Lei, GF; Liu, CX; Sun, RP; Yang, L; Zhang, HJ, 2008) |
| "Memantine, a N-methyl-D-aspartate (NMDA) receptor antagonist, inhibits hematoma expansion and celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces perihematomal inflammation in intracerebral hemorrhage." | 3.74 | Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. ( Chu, K; Jung, KH; Kim, JM; Kim, M; Lee, ST; Park, DK; Roh, JK; Sinn, DI; Song, EC, 2007) |
| " A human breast cancer cell line, MDA-MB-231, was implanted in 30 female homozygotous athymic rats that were alternately assigned to either a drug treatment group that received celecoxib on a daily basis for 7 days or a control group that received saline." | 3.74 | MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. ( Brasch, RC; Floyd, E; Fournier, LS; Fu, Y; Lucidi, V; Miller, T; Novikov, V; Shames, DM, 2007) |
| "The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia." | 3.74 | Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. ( Kita, Y; Murata, Y; Okumura, T; Sakakibara, A, 2008) |
| " To clarify the role of COX-2 in atherosclerosis, we conducted a study to test whether the COX-2 inhibitor, celecoxib, prevents the development and progression of the atherosclerotic process." | 3.74 | The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice. ( Jacob, S; Lanza-Jacoby, S; Laury-Kleintop, L, 2008) |
| "The present study was planned to evaluate the individual and combined effects of selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, and omega-3 fatty acid on the gingival tissue levels of prostaglandin E2 (PGE2), prostaglandin F2alpha (PGF2alpha), leukotriene B4 (LTB4), and platelet activating factor (PAF) in endotoxin-induced periodontitis in rats." | 3.73 | Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats. ( Atilla, G; Baylas, H; Berdeli, AH; Buduneli, E; Buduneli, N; Vardar, S, 2005) |
| "A series of 90 rats underwent a duodenoesophageal reflux surgery were divided into 2 groups: the control group was given a commercial chow and the celecoxib group experimental chow containing celecoxib." | 3.73 | [A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats]. ( Fujimura, T; Miwa, K; Oyama, K, 2005) |
| "Growth inhibitory effects of celecoxib were evaluated in Y79 and Weri-RB1 human retinoblastoma cell lines by WST-1 cell proliferation assay." | 3.73 | Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. ( Grossniklaus, HE; Howard, SA; Lin, ET; O'Brien, JM; Shah, HR; Tong, CT; Van Quill, KR, 2005) |
| " In this study, we examined a dose-dependent effect of a cyclooxygenase-2 (COX-2) inhibitor, celecoxib against transgenic adenocarcinoma of the mouse prostate." | 3.73 | Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. ( Narayanan, BA; Narayanan, NK; Pttman, B; Reddy, BS, 2006) |
| "We found for the first time that (a) both celecoxib and exisulind as dietary supplements induce strong inhibitory effects against prostate cancer at doses of 800 and 500 ppm, respectively, after 16 weeks; (b) the histologic analysis of the dorsolateral prostate after 2 weeks of treatment indicated a reduction of PIN lesions from 75% to 19% with celecoxib and to 16% with exisulind; (c) more importantly, those few PINs and adenocarcinomas in the groups treated with celecoxib or exisulind showed more apoptotic cells, lower levels of proliferating cell nuclear antigen, and a lower number of mitotic cells." | 3.72 | Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. ( Narayanan, BA; Narayanan, NK; Pittman, B; Reddy, BS, 2004) |
| "To investigate the action of celecoxib (a selective COX-2 inhibitor) in a rat model of colitis induced by trinitrobenzene sulfonic acid (TNBS)." | 3.72 | Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. ( Dong, XY; Lu, YM; Zhang, L, 2004) |
| " We used the adenomatous polyposis coli (Apc) mutant Min mouse model to determine whether the selective COX-2 inhibitor celecoxib is effective for adenoma prevention and/or regression, and whether it might be safer than the nonselective NSAID previously shown to be most effective in this model, piroxicam." | 3.70 | The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. ( Cole, CE; Jacoby, RF; Kelloff, G; Lubet, RA; Seibert, K, 2000) |
| " In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer." | 3.70 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. ( Grubbs, CJ; Hill, DL; Kelloff, GJ; Koki, AT; Leahy, KM; Lubet, RA; Masferrer, JL; Seibert, K; Steele, VE, 2000) |
| "Celecoxib was administered as 400 mg, twice daily starting on day 2 of cycle 1." | 2.73 | Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ( Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF, 2007) |
| "Melanoma is a model tumor in immuno-oncology." | 2.66 | COX-2 as a potential biomarker and therapeutic target in melanoma. ( Bâldea, I; Gabriela Filip, A; Hopârtean, A; Kacso, T; Kutasi, E; Lupu, M; Stretea, R; Tudor, DV, 2020) |
| "The low survival rate of patients with pancreatic cancer points towards an increased need for novel therapeutic and chemopreventive strategies and also early detection of this disease." | 2.46 | Chemoprevention strategies for pancreatic cancer. ( Brand, RE; Singh, SV; Stan, SD, 2010) |
| " Epidemiologic data showed that chronic intake of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) could reduce the incidence of colorectal cancer." | 2.42 | Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. ( Chen, BD; Chou, TH; Chu, AJ, 2004) |
| "Intervertebral disc degeneration (IDD) has been identified as one of the predominant factors leading to persistent low back pain and disability in middle-aged and elderly people." | 1.91 | Low-dose celecoxib-loaded PCL fibers reverse intervertebral disc degeneration by up-regulating CHSY3 expression. ( Cao, P; Chen, H; Hu, B; Li, J; Liang, L; Wang, J; Wang, Y; Wei, L; Wu, J; Wu, X; Xiao, Q; Xie, X; Xu, C; Yang, C; Yu, W; Zang, F; Zhang, R; Zhang, T; Zheng, G, 2023) |
| " However, the links between low NO bioavailability and COX-2 overexpression in LSECs are unknown." | 1.62 | Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress. ( Gao, J; Jia, X; Liu, R; Tai, Y; Tang, C; Tang, S; Tong, H; Zhang, L; Zhao, C, 2021) |
| "Celecoxib treatment decreased polyubiquitinated protein load and ER stress marker expression such as glucose-related protein 78 (GRP78), C/EBP (CCAAT/enhancer-binding protein) homologous protein (CHOP), and caspase 12 after 48 h of reperfusion." | 1.62 | Celecoxib-Dependent Neuroprotection in a Rat Model of Transient Middle Cerebral Artery Occlusion (tMCAO) Involves Modifications in Unfolded Protein Response (UPR) and Proteasome. ( Anuncibay-Soto, B; Fernández-López, A; Font-Belmonte, E; González-Rodríguez, P; Pérez-Rodríguez, D; Santos-Galdiano, M; Ugidos, IF, 2021) |
| "Mechanical allodynia, heat hyperalgesia, biased weight-bearing, and hindpaw thickness were assessed 0." | 1.62 | Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats. ( Britch, SC; Craft, RM; Hewitt, KA, 2021) |
| "Metformin was administered orally every day to rats with OA." | 1.62 | Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021) |
| "The animal models of liver fibrosis induced with TAA were established in rats and in intestinal epithelial-specific COX-2 knockout mice." | 1.62 | Inhibition of cyclooxygenase-2 enhanced intestinal epithelial homeostasis via suppressing β-catenin signalling pathway in experimental liver fibrosis. ( Gao, J; Ma, X; Tai, Y; Tang, C; Tang, S; Tong, H; Zhang, L; Zhao, C, 2021) |
| " Nanomedicine has played a crucial role in improving the efficacy of treatment by controlling the release of pharmacologically active ingredients to increase bioavailability and achieve uniform and targeted delivery of drug." | 1.62 | Characterization and in vivo evaluation of nanoformulations in FCA induced rheumatoid arthritis in rats. ( Aslam, B; Faisal, MN; Muhammad, F; Siddique, R, 2021) |
| " CDDP-induced nephrotoxicity (CIN) is one of the most severe adverse events associated with the use of CDDP." | 1.56 | Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo. ( Furugen, A; Iseki, K; Kobayashi, M; Narumi, K; Okamoto, K; Saito, Y, 2020) |
| "Arthrofibrosis is a common complication following total knee arthroplasty caused by pathologic fibroblast activation and excessive collagen deposition around a synovial joint leading to debilitating loss of motion." | 1.51 | Inhibition of COX-2 Pathway as a Potential Prophylaxis Against Arthrofibrogenesis in a Rabbit Model of Joint Contracture. ( Abdel, MP; Berry, DJ; Bolon, B; Carter, JM; Jay, AG; Jones, CR; Lewallen, EA; Limberg, AK; Morrey, ME; Paradise, CR; Reina, N; Robin, JX; Salib, CG; Sanchez-Sotelo, J; Tibbo, ME; Trousdale, WH; Turner, TW; van Wijnen, AJ, 2019) |
| "Depression was induced by IFNα (16 × 105 IU/kg, SC) for six consecutive days." | 1.51 | Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice. ( Hajhashemi, V; Mesripour, A; Shahnooshi, S, 2019) |
| "Depression is considered a neuropsychiatric condition which is associated with neuronal injury within specific brain regions." | 1.51 | COX-2 inhibition rescues depression-like behaviors via suppressing glial activation, oxidative stress and neuronal apoptosis in rats. ( Fan, C; Feng, YB; Li, Y; Shen, J; Song, Q; Wang, L; Wang, P; Yu, SY, 2019) |
| "Celecoxib did not inhibit the progression of initiated HO in the patients in whom HO was diagnosed, whereas those who received celecoxib after surgery had lower morbidity." | 1.51 | Celecoxib cannot inhibit the progression of initiated traumatic heterotopic ossification. ( Li, F; Mao, D; Mi, J; Pan, X; Rui, Y; Zhang, X, 2019) |
| "The celecoxib treatment decreased such rats to 0, 0, 0, and 13." | 1.51 | Effect of celecoxib on protein expression of FAK and Cx43 in DMBA induced rat tongue carcinoma cells. ( Guo, B; Li, YS; Shan, BZ; Sun, XF, 2019) |
| " The prostate tissue penetration and related pharmacokinetic parameters were evaluated by non-compartmental analysis." | 1.48 | Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue. ( Radhakrishnan, J; Radhakrishnan, R; Yellepeddi, VK, 2018) |
| "Left sciatic nerve ligation was used as neuropathic pain model." | 1.48 | Efficacy and safety of combined low doses of either diclofenac or celecoxib with gabapentin versus their single high dose in treatment of neuropathic pain in rats. ( Abdelwahab, S; Abdelzaher, WY; Ibrahim, MA; Rofaeil, RR, 2018) |
| "Celecoxib has been explored as a possible treatment of liver fibrosis with contradictory results, depending on the model." | 1.48 | Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury. ( Hammock, BD; Harris, TR; Hwang, SH; Imai, DM; Kodani, S; Rand, AA; Yang, J, 2018) |
| "Kartogenin (KGN) is a small drug-like molecule that induces chondrogenesis in mesenchymal stem cells (MSCs)." | 1.48 | Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10. ( Cho, KH; Cho, ML; Choi, J; Jung, K; Kim, SJ; Kwon, JY; Lee, CY; Lee, SH; Na, HS; Park, SH; Shin, DY, 2018) |
| "Celecoxib treatment improved the neurologic deficit, reduced the infarct volume by 50% after 48 hours of reperfusion, and resulted in a reduced percentage of SNL areas and microglia and astroglia reactivity after 48 hours of reperfusion." | 1.48 | Celecoxib Treatment Improves Neurologic Deficit and Reduces Selective Neuronal Loss and Glial Response in Rats after Transient Middle Cerebral Artery Occlusion. ( Anuncibay-Soto, B; Fernández-López, A; Font-Belmonte, E; Pérez-García, CC; Pérez-Rodríguez, D; Santos-Galdiano, M; Ugidos, IF, 2018) |
| "Further, it induced cardiac hypertrophy, detected in terms of greater heart weight index and cardiomyocyte cross-sectional area and produced interstitial and perivascular fibrosis." | 1.46 | Celecoxib aggravates cardiac apoptosis in L-NAME-induced pressure overload model in rats: Immunohistochemical determination of cardiac caspase-3, Mcl-1, Bax and Bcl-2. ( Abo-Elmatty, DM; El-Baz, AA; Ibrahim, A; Mosaad, SM; Moustafa, YM; Zaitone, SA, 2017) |
| "We tested whether this parameter and tactile allodynia, the standard pain measure in preclinical studies, show parallels in their response to analgesics and basic mechanisms." | 1.46 | Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia. ( Cañizares, FJ; Cobos, EJ; Entrena, JM; Fernández-Segura, E; Montilla-García, Á; Perazzoli, G; Portillo-Salido, E; Tejada, MÁ, 2017) |
| "Cotreatment with celecoxib and 5-FU partially blocked AKT phosphorylation, although no significant changes in total AKT protein levels were detected." | 1.46 | Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production. ( Ahn, SH; Choi, JJ; Kim, YH; Kwon, SK; Lee, DY; Oh, SM; Park, SW; Shin, ES; Sung, MW, 2017) |
| "An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and outcomes has recently emerged from clinical and animal studies." | 1.46 | Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea. ( Almendros, I; Campillo, N; Farré, R; Gozal, D; Montserrat, JM; Navajas, D; Nonaka, PN; Picado, C; Roca-Ferrer, J; Torres, M; Vilaseca, A, 2017) |
| "Celecoxib treatment led to decreased PGE2 and corticosterone levels, reduced proliferation and increased apoptosis of adrenocortical cells, and decreased steroidogenic gene expression." | 1.43 | Celecoxib reduces glucocorticoids in vitro and in a mouse model with adrenocortical hyperplasia. ( Berthon, A; Faucz, FR; Liu, S; Martinez, A; Sahut-Barnola, I; Saloustros, E; Salpea, P; Starost, MF; Stratakis, CA; Szarek, E, 2016) |
| "Treatment with celecoxib resulted in G1 cell cycle arrest, induction of apoptosis, inhibition of cellular adhesion and invasion and reduction of expression of hTERT mRNA and COX-2 protein in all of the ovarian cancer cell lines." | 1.43 | The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. ( Bae-Jump, VL; Gehrig, PA; Han, X; Jones, HM; Schuler, KM; Sheng, X; Suri, A; Zhong, Y; Zhou, C, 2016) |
| "The prognosis of muscle-invasive bladder cancer with metastasis is poor." | 1.43 | A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells. ( Aono, Y; Horinaka, M; Miki, T; Morioka, Y; Sakai, T; Takamura, T; Taniguchi, T; Toriyama, S; Ukimura, O; Yasuda, S, 2016) |
| "Inflammation is a potent promoter of tumor metastasis." | 1.42 | Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway. ( Bi, Y; Han, M; Jiang, M; Li, S; Xu, J; Xu, X, 2015) |
| "CSA hypertension was associated with renal perivascular fibrosis and divergent changes in immunohistochemical signals of renal arteriolar ETA (increases) and ETB (decreases) receptors." | 1.42 | Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling. ( Ali, RM; El-Gowelli, HM; El-Mas, MM; Helmy, MW, 2015) |
| "Diclofenac treatment produced dose-related reversal of CRANE at 0." | 1.42 | Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats. ( Bannon, AW; Joshi, SK; Zhu, CZ, 2015) |
| "Captopril prevented the increase in blood pressure, which was associated with lower plasma Ang II and increased COX-2-derived 6-Keto-PGF(1α) at day 2 and plasma Ang (1-7) at day 19." | 1.42 | Early co-expression of cyclooxygenase-2 and renin in the rat kidney cortex contributes to the development of N(G)-nitro-L-arginine methyl ester induced hypertension. ( Del Valle-Mondragón, L; Guzmán-Hernández, EA; Ibarra-Barajas, M; Pastelín-Hernández, G; Sánchez-Mendoza, MA; Villalobos-Molina, R, 2015) |
| " In order to probe an alternative dosing design that would preclude this effect, we studied the efficacy of a low dose of the antidepressant imipramine (7 mg/kg/day) delivered via food pellets." | 1.42 | Animal Models of Depression and Drug Delivery with Food as an Effective Dosing Method: Evidences from Studies with Celecoxib and Dicholine Succinate. ( Araújo-Correia, M; Cline, BH; Costa-Nunes, JP; Dolgov, O; Kubatiev, A; Markova, N; Steinbusch, HW; Strekalova, T; Valença, A; Yeritsyan, N, 2015) |
| "Celecoxib- treated OIR mice reduced the retinal neovascular tufts and the levels of VEGF and HIF-1α." | 1.42 | Celecoxib attenuates retinal angiogenesis in a mouse model of oxygen-induced retinopathy. ( Cai, N; Chen, L; Liu, N, 2015) |
| " After the hydrogel was shown to be biocompatible and safe, an in vivo dose-response study was performed in order to determine safety and efficacy of the pNIPAAM MgFe-LDH hydrogel for intradiscal controlled delivery of CXB." | 1.42 | Biocompatibility and intradiscal application of a thermoreversible celecoxib-loaded poly-N-isopropylacrylamide MgFe-layered double hydroxide hydrogel in a canine model. ( Craenmehr, EG; Creemers, LB; Dhert, WJ; Grinwis, GC; Kranenburg, HJ; Langelaan, ML; Meij, BP; Papen-Botterhuis, NE; Plomp, SG; Riemers, FM; Tellegen, AR; Tryfonidou, MA; Willems, N; Yang, HY, 2015) |
| "Peritonitis was induced in mice by intraperitoneal injection of LPS (E." | 1.42 | Roles of mPGES-1, an inducible prostaglandin E synthase, in enhancement of LPS-induced lymphangiogenesis in a mouse peritonitis model. ( Akira, S; Hosono, K; Kurashige, C; Majima, M; Matsuda, H; Okamoto, H; Sekiguchi, K; Tsuru, S; Uematsu, S, 2015) |
| "Celecoxib and citrate have been shown to possess antitumor activity in a variety of cancer cells." | 1.42 | Citrate and celecoxib induce apoptosis and decrease necrosis in synergistic manner in canine mammary tumor cells. ( Farsinejad, A; Panahi, N; Safi, S; Vahidi, R, 2015) |
| " The lead compound demonstrated very good oral bioavailability in mice, slow metabolic degradation, modest distribution into the brain and a remarkable anti-inflammatory efficacy in carrageenan-induced mouse paw edema model." | 1.40 | Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core. ( Gavalas, A; Geronikaki, A; Hammock, B; Hwang, SH; Iurchenko, V; Ivanenkov, Y; Krasavin, M; Morisseau, C; Mujumdar, P; Sarnpitak, P; Zozulya, S, 2014) |
| "Treatment with celecoxib and triamcinolone significantly reduced total leukocyte count by 40% (P = 0." | 1.40 | The safety, pharmacokinetics, and efficacy of intraocular celecoxib. ( Kim, SJ; Kompella, UB; Shah, R; Sheng, J; Toma, H; Vooturi, SK, 2014) |
| "Based on X-ray and histological results, heterotopic ossification was assessed." | 1.40 | [Effects of selective and non-selective cyclooxygenase 2 inhibitors on heterotopic ossification in rat model with Achilles tenotomy]. ( Shi, W; Wu, J; Xiao, H; Xue, F; Zhao, H, 2014) |
| " Long-term administration of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, can ameliorate hepatic fibrosis." | 1.40 | Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes. ( Gao, JH; Huang, ZY; Liu, ZX; Lu, YY; Tang, CW; Tong, H; Wen, SL; Yang, WJ, 2014) |
| "We recently demonstrated that both murine and human carcinomas grow significantly slower in mice on low carbohydrate (CHO), high protein diets than on isocaloric Western diets and that a further reduction in tumor growth rates occur when the low CHO diets are combined with the cyclooxygenase-2 inhibitor, celecoxib." | 1.40 | A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis. ( Adomat, HH; Bennewith, KL; Dang, NH; Guns, ES; Hamilton, MJ; Ho, VW; Hsu, BE; Krystal, G; Samudio, I; Weljie, A, 2014) |
| "Pain is the most common complaint in the medical field and the identification of novel compounds that can effectively treat painful states without causing side effects remains a major challenge in biomedical research." | 1.40 | Antinociceptive effect of 3-(4-fluorophenyl)-5-trifluoromethyl-1H-1-tosylpyrazole. A Celecoxib structural analog in models of pathological pain. ( Bonacorso, HG; Correa, MS; Ferreira, J; Oliveira, SM; Otuki, MF; Paim, GR; Prudente, AS; Silva, CR; Wentz, AP, 2014) |
| "The underlying causes of endometrial cancer (EMC) are poorly understood, and treatment options for patients with advanced stages of the disease are limited." | 1.40 | Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer. ( Cappelletti, M; Daikoku, T; Dey, SK; Ellenson, LH; Hossain, MM; Terakawa, J; Yang, P; Yoshie, M, 2014) |
| "Furthermore, breast cancer cells exposed to the involuting mammary microenvironment acquired prolymphangiogenic properties that contributed to peritumor lymphatic expansion, tumor size, invasion, and distant metastases." | 1.40 | Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. ( Betts, CB; Borges, VF; Guo, Q; Jindal, S; Kapoor, P; Lyons, TR; Martinson, HA; Schedin, P, 2014) |
| "Pretreatment with naproxen in the WRS model caused an increase in severity of damage and a decrease in NOS activity." | 1.40 | Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage. ( Biletska, L; Bondarchuk, T; Fomenko, I; Panasyuk, N; Sklyarov, A; Wallace, JL, 2014) |
| "Disease progression was monitored utilizing micro-magnetic resonance imaging (MRI), micro-computed tomography (CT) and histology." | 1.40 | Development and reliability of a multi-modality scoring system for evaluation of disease progression in pre-clinical models of osteoarthritis: celecoxib may possess disease-modifying properties. ( Doschak, MR; Fallone, BG; Jaremko, JL; Lambert, RG; Maksymowych, WP; Panahifar, A; Tessier, AG, 2014) |
| "However, the effects of celecoxib on heterotopic ossification at other locations remain unclear." | 1.39 | Celecoxib inhibits the heterotopic ossification in the rat model with Achilles tenotomy. ( Bai, X; Cui, Z; Jin, D; Liu, F; Wang, L; Yu, B; Zhang, K; Zhang, S, 2013) |
| "Celecoxib was much less efficient in reducing tumourigenesis in MNU-treated mice (by 23%; 1686 mm(3)) than in untreated mice (76%; 58 mm(3))." | 1.39 | N-methylnitrosourea aggravates gastrointestinal polyposis in Lkb1+/- mice. ( Gao, Y; Mäkelä, TP; Ristimäki, AP; Udd, L, 2013) |
| "Celecoxib treatment greatly reduced the tortuous hepatic portal venules." | 1.39 | Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. ( Gao, JH; Huang, ZY; Liu, ZX; Lu, YY; Tang, CW; Tong, H; Wen, SL; Yang, WJ, 2013) |
| "The underlying mechanisms of nonalcoholic steatohepatitis (NASH) are poorly understood, and little is known about hepatocellular apoptosis in NASH." | 1.39 | Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats. ( Chen, M; Cheng, Q; Huang, C; Li, N; Qian, Z; Shi, G; Wang, X; Xu, S; Zheng, J, 2013) |
| "Celecoxib is a selective cyclooxygenase-2 (COX2) inhibitor." | 1.39 | A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation. ( Alloza, I; Chiba, A; Di Penta, A; Miyake, S; Vandenbroeck, K; Villoslada, P; Wyssenbach, A; Yamamura, T, 2013) |
| "Celecoxib was chosen as a comparator, given its clinical efficacy for alleviating pain in osteoarthritis patients and its peripheral and central pharmacological action." | 1.39 | Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. ( Baker, SJ; Bannon, A; Beaver, J; Cassar, S; Chandran, P; Day, M; Fox, GB; Hart, M; Honore, P; Hooker, BA; Joshi, SK; Kamath, RV; Medema, JK; Mikusa, JP; Rajagovindan, R; Tovcimak, A; Upadhyay, J; Wald, MJ, 2013) |
| "Cerebral vasospasm after subarachnoid hemorrhage (SAH) is characterized by prolonged severe constriction of the basilar artery, which often leads to ischemic brain damage." | 1.39 | Vascular KCNQ (Kv7) potassium channels as common signaling intermediates and therapeutic targets in cerebral vasospasm. ( Brueggemann, LI; Byron, KL; Kumar, L; Mani, BK; O'Dowd, J; Ross, M, 2013) |
| "Benzothiazole amides were identified as TRPV1 antagonists from high throughput screening using recombinant human TRPV1 receptor and structure-activity relationships were explored to pinpoint key pharmacophore interactions." | 1.38 | Potent and orally efficacious benzothiazole amides as TRPV1 antagonists. ( Besidski, Y; Brown, W; Bylund, J; Dabrowski, M; Dautrey, S; Griffin, AM; Harter, M; Horoszok, L; Hu, Y; Johnson, D; Johnstone, S; Jones, P; Kers, I; Kolmodin, K; Labarre, M; Labrecque, D; Laird, J; Leclerc, S; Lundström, T; Martino, J; Maudet, M; Munro, A; Nylöf, M; Penwell, A; Rotticci, D; Slaitas, A; Sundgren-Andersson, A; Svensson, M; Terp, G; Villanueva, H; Walpole, C; Zemribo, R, 2012) |
| "Autosomal dominant polycystic kidney disease (ADPKD) is a progressive chronic kidney disease." | 1.38 | Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. ( Fu, LL; Mei, CL; Wang, NS; Xu, T; Ye, CY; Yu, SQ, 2012) |
| "Celecoxib has a positive effect on human osteoarthritic cartilage, but the mechanisms remain unclear." | 1.38 | Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte. ( An, H; Jiang, D; Luo, X; Ou, Y; Quan, Z; Tan, C; Tang, K, 2012) |
| "The celecoxib treatment also protected the mice from aortic rupture and death." | 1.38 | Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype. ( Gitlin, JM; Loftin, CD; Mukherjee, K, 2012) |
| "Celecoxib treatment decreased the incidence of EA in rats undergoing EJA with H." | 1.37 | Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux. ( Gao, PP; Li, J; Liu, FX; Wang, J; Wang, WH, 2011) |
| "In patients with ESRD who underwent parathyroidectomy, clusters of cells within the parathyroid glands had increased COX2 expression." | 1.37 | Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD. ( Chen, J; Gu, Y; Hao, CM; Li, H; Lu, Y; Qiu, J; Wang, S; Wang, X; Yang, J; Zhang, L; Zhang, Q, 2011) |
| " Pharmacokinetic parameters and their between animal variability were obtained using standard non-compartmental analysis as well as a compartmental analysis using nonlinear mixed effects modeling." | 1.37 | Pharmacokinetics of a combination of Δ9-tetrahydro-cannabinol and celecoxib in a porcine model of hemorrhagic shock. ( Mehrotra, N; Meibohm, B; Moore, BM; Vaddady, PK; Yates, CR; Zhang, X, 2011) |
| "Omeprazole treatment did not result in mucosal injury or inflammation; however, there were marked shifts in numbers and types of enteric bacteria, including a significant reduction (∼80%) of jejunal Actinobacteria and Bifidobacteria spp." | 1.37 | Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. ( Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL, 2011) |
| "The prognosis of breast cancer in young women is influenced by reproductive history." | 1.37 | Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. ( Borges, VF; Conklin, MW; Eliceiri, KW; Keely, PJ; Lyons, TR; Marusyk, A; O'Brien, J; Schedin, P; Tan, AC, 2011) |
| "Amfenac treatment failed to inhibit hypoxia-induced VEGF production." | 1.36 | The effects of nepafenac and amfenac on retinal angiogenesis. ( Bingaman, DP; Clark, ML; Penn, JS; Yang, R; Yanni, SE, 2010) |
| "Chondrosarcomas are resistant to conventional chemo- and radiotherapy." | 1.36 | COX-2 expression in chondrosarcoma: a role for celecoxib treatment? ( Bovée, JV; Briaire-de Bruijn, I; Kalinski, T; Llombart-Bosch, A; Machado, I; Meijer, D; Schrage, YM; Taminiau, AH; van den Akker, BE, 2010) |
| "Celecoxib is a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2." | 1.36 | Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model. ( Buttars, S; Done, SJ; Tran-Thanh, D; Wen, Y; Wilson, C, 2010) |
| "Human tongue squamous cell carcinoma tumor cells Tca8113 and a mouse model with Tca8113 cells were used to study the growth inhibition of cisplatin enhanced by celecoxib." | 1.36 | Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro. ( Ding, YQ; Li, WZ; Li, ZG; Wang, XY; Zhang, JH, 2010) |
| "Indomethacin (sc) reversed CG-induced hyperalgesia only to basal levels (an anti-hyperalgesic effect)." | 1.36 | Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia. ( Bakhle, YS; Correa, JD; Dos Reis, WG; Ferreira-Alves, DL; Francischi, JN; Paiva-Lima, P; Rezende, RM, 2010) |
| "Glycogen was decreased by CCl(4), while celecoxib partially prevented and reversed this effect." | 1.36 | Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat. ( Castro-Sánchez, L; Chávez, E; Moreno, MG; Muriel, P; Salazar, EP; Segovia, J; Shibayama, M; Tsutsumi, V; Vergara, P, 2010) |
| "Pretreatment with celecoxib (2." | 1.36 | Anticonvulsant effect of celecoxib on pentylenetetrazole-induced convulsion: Modulation by NO pathway. ( Dehpour, AR; Hajimirzabeigi, A; Khalilzadeh, O; Maleki, F; Zandieh, A; Zandieh, B, 2010) |
| "Alveolar bone loss was evaluated morphometrically under a stereomicroscope." | 1.35 | The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis. ( Atilla, G; Baylas, H; Buduneli, E; Buduneli, N; Sorsa, T; Turkoglu, O; Vardar-Sengul, S; Wahlgren, J, 2008) |
| "Arachidonic acid metabolites have been implicated in development of periodontal disease, especially those derived from the cyclo-oxygenase (COX) pathway." | 1.35 | Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats. ( Caliari, MV; Duarte, ID; Francischi, JN; Maltos, KL; Pacheco, CM; Queiroz-Junior, CM, 2009) |
| "Skin cancer is the most common cancer, and often occurs in the head and neck region." | 1.35 | Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. ( Fegn, L; Wang, Z, 2009) |
| "Body weight was increased significantly and similarly in HFa, HFa-Cel, and HFa-Mes." | 1.35 | COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. ( Chan, PC; Chen, CH; Chiang, CF; Hsieh, PS; Jin, JS; Shih, KC, 2009) |
| "Oral mucositis is a severe, dose-limiting side effect of radio(chemo)therapy for head and neck tumors." | 1.35 | Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. ( Dörr, W; Haagen, J; Krohn, H; Röllig, S; Schmidt, M; Wolfram, K, 2009) |
| "Lung and bone metastasis and the associated inflammatory milieu were evaluated in the arthritic versus the non-arthritic mice." | 1.35 | Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. ( Das Roy, L; Gruber, HE; Mukherjee, P; Pathangey, LB; Schettini, JL; Tinder, TL, 2009) |
| "Celecoxib treatment resulted in a significant reduction in the proliferation of H." | 1.35 | Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. ( Chang, LL; Hu, HM; Jan, CM; Kuo, CH; Tsai, PY; Wang, JY; Wang, WM; Wu, DC; Wu, IC; Yang, SF, 2009) |
| "Traumatic heterotopic ossification (HO) is a common clinical condition associated with various orthopedic procedures that involve injury to soft tissues near bone." | 1.35 | The effects of COX-1 and COX-2 inhibitors on prostaglandin synthesis and the formation of heterotopic bone in a rat model. ( Boursiquot, R; Helfet, DL; Lane, JM; Macdonald, DE; Maddula, S; Raghavan, D; Rapuano, BE; Tomin, E, 2008) |
| " The present study investigated the importance of endogenous prostaglandin production and nitric oxide (NO) in the renal haemodynamic and excretory responses to ischaemia-reperfusion both normally and in the hypertensive state by chronic administration of cyclo-oxygenase (COX) inhibitors." | 1.35 | Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation. ( Johns, EJ; Knight, S, 2008) |
| "Celecoxib/STZ treatments produced a significant loss of learning and memory." | 1.35 | Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil. ( Sharma, B; Singh, M; Singh, N, 2008) |
| "While current breast cancer chemoprevention strategies using selective estrogen response modulators and aromatase inhibitors are quite successful, their effects are limited to hormonally responsive breast cancer." | 1.35 | Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. ( Gould, MN; Haag, JD; Lubet, RA; Mau, B; Woditschka, S, 2008) |
| "Itching was induced by an intradermal injection of trypsin in the mouse neck." | 1.35 | Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice. ( Brain, SD; Calixto, JB; Costa, R; Fernandes, ES; Juliano, L; Lima-Garcia, JF; Manjavachi, MN; Marotta, DM; Paszcuk, AF; Quintão, NL, 2008) |
| " Increasing evidence suggests that an inflammatory reaction accompanies the pathological processes caused by Cyclooxygenase (COX) seen in many neurodegenerative disorders, including PD and according to the recent researches chronic use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) decreases the risk of PD in human." | 1.34 | Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease. ( Abid, KM; Ardestani, MS; Hemmati, A; Mehrab, H; Moghaddam, HF; Nazari, Z, 2007) |
| "Celecoxib treatment at a dose of 4 mg/kg/day reduced fracture callus prostaglandin E2 and F(2alpha) levels by >60%." | 1.34 | Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. ( O'Connor, JP; Simon, AM, 2007) |
| " In conclusion, our study suggests that chronic administration of celecoxib may have a damaging effect on kidney, as evident through altered histopathology and renal functions." | 1.34 | Role of oxidative stress in celecoxib-induced renal damage in wistar rats. ( Aggarwal, R; Agnihotri, N; Dutta, N; Gupta, S; Sarotra, P, 2007) |
| "Lung cancer is the leading cause of cancer deaths in the United States." | 1.34 | Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer. ( Crooks, PA; Nakshatri, H; Neelakantan, S; Ralstin, M; Schmidt, CM; Sweeney, CJ; Vegeler, RC; Wu, H; Yip-Schneider, MT, 2007) |
| "Swelling and mechanical and thermal hyperalgesia were assessed before and for 28 days after the onset of arthritis." | 1.34 | Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. ( Anand, P; Essex, D; Feldmann, M; Inglis, JJ; Notley, CA; Williams, R; Wilson, AW, 2007) |
| "Esophageal and tongue cancers have both been associated with dietary zinc deficiency (ZD), and cyclooxygenase (COX-2) is often overexpressed in these cancers." | 1.33 | Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats. ( Farber, JL; Fong, LY; Jiang, Y; Zhang, L, 2005) |
| "Celecoxib treatment significantly suppressed viral reactivation when given prophylactically by the gastrointestinal route." | 1.33 | Inhibition of cyclooxygenase 2 synthesis suppresses Herpes simplex virus type 1 reactivation. ( Gebhardt, BM; Kaufman, HE; Varnell, ED, 2005) |
| "CION caused ipsilateral cold hyperalgesia between Days 2 and 12, which peaked on Days 4 (sham 15." | 1.33 | Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs. ( Chichorro, JG; Rae, GA; Souza, GE; Zampronio, AR, 2006) |
| " This may be clinically important as this dose of celecoxib can be achieved in human serum following standard anti-inflammatory dosing of 100 mg." | 1.33 | Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. ( Arber, N; Giladi, N; Kazanov, D; Lev-Ari, S; Liberman, E; Sagiv, E; Shpitz, B, 2006) |
| "Over a million nonmelanoma skin cancer cases will be reported in the United States this year alone." | 1.32 | Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. ( Koki, AT; Oberyszyn, TM; Rubal, PA; Wilgus, TA; Zweifel, BS, 2003) |
| "Indomethacin (3 mg/kg) was then compared to celecoxib (4." | 1.32 | Indomethacin and celecoxib improve tendon healing in rats. ( Aspenberg, P; Bylander, B; Forslund, C, 2003) |
| " Swiss-Webster mice were dosed with celecoxib and rofecoxib and challenged with CT in ligated small intestinal loops, and intestinal segments from mice deficient in COX-1 and COX-2 were challenged with CT." | 1.32 | Role of cyclooxygenase enzymes in a murine model of experimental cholera. ( Boldogh, I; Gessell-Lee, DL; Olano, JP; Peterson, JW; Popov, VL, 2003) |
| "3." | 1.32 | Pharmacological characterisation of a rat model of incisional pain. ( Boulet, J; Gottshall, S; Harrison, J; Mark, L; Pearson, M; Walker, K; Whiteside, GT, 2004) |
| "Celecoxib-treated mice also developed fewer tumors (1." | 1.32 | The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. ( Daskalakis, C; Flynn, J; Gallatig, K; Lanza-Jacoby, S; Masferrer, JL; Miller, S; Russo, IH; Sembhi, H; Zweifel, BS, 2003) |
| "Ibuprofen treatment reversed PGE2 levels in injured nerves and DRG, whereas celecoxib blocked increased PGE2 levels only in nerves." | 1.32 | Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. ( Marziniak, M; Schäfers, M; Sommer, C; Sorkin, LS; Yaksh, TL, 2004) |
| " There was a reduction in PGE2 levels on chronic administration of celecoxib in DSS-treated animals." | 1.32 | Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. ( Jain, NK; Kulkarni, SK; Patil, CS; Singh, VP, 2004) |
| "In addition, formalin-induced secondary hyperalgesia was locally prevented by pre-but not post-celecoxib treatment." | 1.32 | Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. ( Avila, MN; da Motta, PG; Duarte, ID; Francischi, JN; Tatsuo, MA; Veiga, AP, 2004) |
| "Celecoxib treatment initiating before polyposis (3." | 1.32 | Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. ( Järvinen, HJ; Katajisto, P; Lahesmaa, AM; Lepistö, A; Mäkelä, TP; Ristimäki, AP; Rossi, DJ; Udd, L; Ylikorkala, A, 2004) |
| "Main parameter was thrombus weight." | 1.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| "The ratios of squamous cell carcinomas to papillomas and of sebaceous gland adenomas to papillomas plus squamous cell carcinomas were increased markedly in transgenic mice treated with DMBA alone compared with DMBA/phorbol 12-myristate 13-acetate-treated transgenic and wild-type mice." | 1.31 | Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. ( Berger, I; Furstenberger, G; Marks, F; Muller-Decker, K; Neufang, G; Neumann, M, 2002) |
| "Celecoxib treatment significantly delayed the onset of weakness and weight loss and prolonged survival by 25%." | 1.31 | Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. ( Almer, G; Drachman, DB; Dykes-Hoberg, M; Frank, K; Przedborski, S; Rothstein, JD; Teismann, P, 2002) |
| "Colitis was induced by intracolonic administration of trinitrobenzene sulfonic acid." | 1.31 | Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. ( Ajuebor, MN; Singh, A; Wallace, JL, 2000) |
| "In celecoxib-treated animals, vasodilation in response to arachidonic acid was reduced significantly compared with controls." | 1.31 | Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. ( Barrett, TD; Crofford, LJ; Driscoll, EM; Hennan, JK; Huang, J; Lucchesi, BR; Park, AM; Willens, DE, 2001) |
| "Celecoxib is an effective and safe chemopreventive agent in UV carcinogenesis." | 1.31 | Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. ( Black, HS; Gerguis, J; Guevara, A; Lewis, AT; Orengo, IF; Phillips, R, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 126 (37.17) | 29.6817 |
| 2010's | 176 (51.92) | 24.3611 |
| 2020's | 37 (10.91) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, SS | 1 |
| Noh, MS | 1 |
| Byun, YJ | 1 |
| Choi, JK | 2 |
| Kim, JY | 1 |
| Lim, KM | 1 |
| Ha, JY | 1 |
| Kim, JK | 1 |
| Lee, CH | 1 |
| Chung, S | 1 |
| Feixas, J | 1 |
| Jiménez, JM | 1 |
| Godessart, N | 1 |
| Puig, C | 1 |
| Soca, L | 1 |
| Crespo, MI | 1 |
| Abouzid, K | 1 |
| Bekhit, SA | 1 |
| Chowdhury, MA | 1 |
| Abdellatif, KR | 2 |
| Dong, Y | 1 |
| Das, D | 1 |
| Suresh, MR | 1 |
| Knaus, EE | 1 |
| Lacerda, RB | 1 |
| de Lima, CK | 1 |
| da Silva, LL | 1 |
| Romeiro, NC | 1 |
| Miranda, AL | 1 |
| Barreiro, EJ | 1 |
| Fraga, CA | 1 |
| Swarbrick, ME | 1 |
| Beswick, PJ | 1 |
| Gleave, RJ | 1 |
| Green, RH | 1 |
| Bingham, S | 1 |
| Bountra, C | 1 |
| Carter, MC | 1 |
| Chambers, LJ | 1 |
| Chessell, IP | 1 |
| Clayton, NM | 1 |
| Collins, SD | 1 |
| Corfield, JA | 1 |
| Hartley, CD | 1 |
| Kleanthous, S | 1 |
| Lambeth, PF | 1 |
| Lucas, FS | 1 |
| Mathews, N | 1 |
| Naylor, A | 1 |
| Page, LW | 1 |
| Payne, JJ | 1 |
| Pegg, NA | 1 |
| Price, HS | 1 |
| Skidmore, J | 1 |
| Stevens, AJ | 1 |
| Stocker, R | 1 |
| Stratton, SC | 1 |
| Stuart, AJ | 1 |
| Wiseman, JO | 1 |
| Abdel-Aziz, AA | 3 |
| ElTahir, KE | 3 |
| Asiri, YA | 2 |
| El-Sayed, MA | 2 |
| Abdel-Aziz, NI | 2 |
| El-Azab, AS | 2 |
| Chiu, HC | 1 |
| Lee, SL | 1 |
| Kapuriya, N | 1 |
| Wang, D | 2 |
| Chen, YR | 2 |
| Yu, SL | 1 |
| Kulp, SK | 1 |
| Teng, LJ | 1 |
| Chen, CS | 1 |
| Besidski, Y | 1 |
| Brown, W | 1 |
| Bylund, J | 1 |
| Dabrowski, M | 1 |
| Dautrey, S | 1 |
| Harter, M | 1 |
| Horoszok, L | 1 |
| Hu, Y | 2 |
| Johnson, D | 1 |
| Johnstone, S | 1 |
| Jones, P | 1 |
| Leclerc, S | 1 |
| Kolmodin, K | 1 |
| Kers, I | 1 |
| Labarre, M | 1 |
| Labrecque, D | 1 |
| Laird, J | 1 |
| Lundström, T | 1 |
| Martino, J | 1 |
| Maudet, M | 1 |
| Munro, A | 1 |
| Nylöf, M | 1 |
| Penwell, A | 1 |
| Rotticci, D | 1 |
| Slaitas, A | 1 |
| Sundgren-Andersson, A | 1 |
| Svensson, M | 1 |
| Terp, G | 1 |
| Villanueva, H | 1 |
| Walpole, C | 1 |
| Zemribo, R | 1 |
| Griffin, AM | 1 |
| Lokwani, DK | 1 |
| Mokale, SN | 1 |
| Shinde, DB | 1 |
| Sarnpitak, P | 1 |
| Mujumdar, P | 1 |
| Morisseau, C | 1 |
| Hwang, SH | 2 |
| Hammock, B | 1 |
| Iurchenko, V | 1 |
| Zozulya, S | 1 |
| Gavalas, A | 1 |
| Geronikaki, A | 1 |
| Ivanenkov, Y | 1 |
| Krasavin, M | 1 |
| Kharbanda, C | 1 |
| Alam, MS | 1 |
| Hamid, H | 1 |
| Javed, K | 2 |
| Bano, S | 1 |
| Dhulap, A | 1 |
| Ali, Y | 1 |
| Nazreen, S | 1 |
| Haider, S | 1 |
| Lobo, MM | 1 |
| Oliveira, SM | 2 |
| Brusco, I | 1 |
| Machado, P | 1 |
| Timmers, LF | 1 |
| de Souza, ON | 1 |
| Martins, MA | 1 |
| Bonacorso, HG | 2 |
| Dos Santos, JM | 1 |
| Canova, B | 1 |
| da Silva, TV | 1 |
| Zanatta, N | 1 |
| Shrivastava, SK | 1 |
| Srivastava, P | 1 |
| Bandresh, R | 1 |
| Tripathi, PN | 1 |
| Tripathi, A | 1 |
| He, LY | 1 |
| Zhang, SS | 1 |
| Peng, DX | 1 |
| Guan, LP | 1 |
| Wang, SH | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Said, MF | 1 |
| Georgey, HH | 1 |
| Mohammed, ER | 1 |
| Wang, H | 1 |
| Cui, E | 1 |
| Li, J | 4 |
| Ma, X | 4 |
| Jiang, X | 1 |
| Du, S | 1 |
| Qian, S | 1 |
| Du, L | 1 |
| Sun, L | 1 |
| Tai, Y | 3 |
| Zhao, C | 3 |
| Zhang, L | 8 |
| Tang, S | 3 |
| Jia, X | 2 |
| Tong, H | 4 |
| Liu, R | 2 |
| Tang, C | 3 |
| Gao, J | 3 |
| Hsia, AW | 1 |
| Jbeily, EH | 1 |
| Mendez, ME | 1 |
| Cunningham, HC | 1 |
| Biris, KK | 1 |
| Bang, H | 1 |
| Lee, CA | 1 |
| Loots, GG | 1 |
| Christiansen, BA | 1 |
| Min, HK | 2 |
| Choi, J | 2 |
| Lee, SY | 2 |
| Lee, AR | 2 |
| Min, BM | 1 |
| Cho, ML | 3 |
| Park, SH | 3 |
| Zhang, XY | 2 |
| Barakat, A | 1 |
| Diaz-delCastillo, M | 1 |
| Vollert, J | 1 |
| Sena, ES | 1 |
| Heegaard, AM | 1 |
| Rice, ASC | 1 |
| Soliman, N | 1 |
| Leitão, AWA | 1 |
| Borges, MMF | 1 |
| Martins, JOL | 1 |
| Coelho, AA | 1 |
| Carlos, ACAM | 1 |
| Alves, APNN | 1 |
| Silva, PGB | 1 |
| Sousa, FB | 1 |
| Kaur, R | 1 |
| Desai, D | 1 |
| Amin, S | 1 |
| Raza, K | 1 |
| Bhalla, A | 1 |
| Yadav, P | 1 |
| Kaushal, N | 1 |
| Hou, PW | 3 |
| Liu, SC | 3 |
| Tsay, GJ | 3 |
| Chang, YS | 3 |
| Huang, HC | 4 |
| Tang, CH | 3 |
| Chang, HH | 3 |
| Wang, Y | 4 |
| Zheng, G | 1 |
| Xie, X | 1 |
| Yu, W | 1 |
| Wang, J | 4 |
| Zang, F | 1 |
| Yang, C | 1 |
| Xiao, Q | 1 |
| Zhang, R | 1 |
| Wei, L | 1 |
| Wu, X | 1 |
| Liang, L | 1 |
| Cao, P | 1 |
| Xu, C | 1 |
| Hu, B | 1 |
| Zhang, T | 2 |
| Wu, J | 2 |
| Chen, H | 1 |
| Montico, F | 3 |
| Lamas, CA | 1 |
| Rossetto, IMU | 1 |
| Baseggio, AM | 1 |
| Cagnon, VHA | 2 |
| Mortensen, R | 1 |
| Clemmensen, HS | 1 |
| Woodworth, JS | 1 |
| Therkelsen, ML | 1 |
| Mustafa, T | 1 |
| Tonby, K | 1 |
| Jenum, S | 1 |
| Agger, EM | 1 |
| Dyrhol-Riise, AM | 1 |
| Andersen, P | 1 |
| Salib, CG | 2 |
| Reina, N | 1 |
| Trousdale, WH | 1 |
| Limberg, AK | 2 |
| Tibbo, ME | 2 |
| Jay, AG | 2 |
| Robin, JX | 1 |
| Turner, TW | 2 |
| Jones, CR | 1 |
| Paradise, CR | 1 |
| Lewallen, EA | 1 |
| Bolon, B | 2 |
| Carter, JM | 2 |
| Berry, DJ | 2 |
| Morrey, ME | 2 |
| Sanchez-Sotelo, J | 2 |
| van Wijnen, AJ | 3 |
| Abdel, MP | 2 |
| Mesripour, A | 1 |
| Shahnooshi, S | 1 |
| Hajhashemi, V | 1 |
| Al Kury, LT | 1 |
| Zeb, A | 1 |
| Abidin, ZU | 1 |
| Irshad, N | 1 |
| Malik, I | 1 |
| Alvi, AM | 1 |
| Khalil, AAK | 1 |
| Ahmad, S | 2 |
| Faheem, M | 1 |
| Khan, AU | 1 |
| Shah, FA | 1 |
| Li, S | 2 |
| Dave, V | 1 |
| Gupta, A | 1 |
| Singh, P | 1 |
| Tak, K | 1 |
| Sharma, S | 1 |
| Song, Q | 1 |
| Feng, YB | 1 |
| Wang, L | 3 |
| Shen, J | 1 |
| Li, Y | 3 |
| Fan, C | 1 |
| Wang, P | 3 |
| Yu, SY | 1 |
| Ghazala, RA | 1 |
| El Medney, A | 1 |
| Meleis, A | 1 |
| Mohie El Dien, P | 1 |
| Samir, H | 1 |
| Valvassori, SS | 2 |
| Tonin, PT | 2 |
| Dal-Pont, GC | 2 |
| Varela, RB | 2 |
| Cararo, JH | 1 |
| Garcia, AF | 1 |
| Gava, FF | 2 |
| Menegas, S | 1 |
| Soares, JC | 2 |
| Quevedo, J | 2 |
| Li, F | 2 |
| Mao, D | 1 |
| Pan, X | 1 |
| Zhang, X | 3 |
| Mi, J | 1 |
| Rui, Y | 1 |
| Shan, BZ | 1 |
| Guo, B | 1 |
| Li, YS | 1 |
| Sun, XF | 1 |
| Xie, Z | 2 |
| Wang, S | 5 |
| Liang, Z | 1 |
| Zeng, L | 1 |
| Lai, R | 1 |
| Ye, Z | 1 |
| Liao, P | 1 |
| Philpott, HT | 1 |
| McDougall, JJ | 1 |
| Oliveira, DH | 1 |
| Sousa, FSS | 1 |
| Birmann, PT | 1 |
| Alves, D | 1 |
| Jacob, RG | 1 |
| Savegnago, L | 1 |
| Tang, B | 1 |
| Guo, ZS | 1 |
| Bartlett, DL | 2 |
| Yan, DZ | 1 |
| Schane, CP | 1 |
| Thomas, DL | 1 |
| Liu, J | 1 |
| McFadden, G | 1 |
| Shisler, JL | 1 |
| Roy, EJ | 1 |
| Liu, L | 3 |
| Karagoz, H | 1 |
| Herneisey, M | 1 |
| Zor, F | 1 |
| Komatsu, T | 1 |
| Loftus, S | 1 |
| Janjic, BM | 1 |
| Gorantla, VS | 1 |
| Janjic, JM | 3 |
| McLaury, AR | 1 |
| Berry, CE | 1 |
| Zhuang, S | 1 |
| Chai, J | 1 |
| Yin, H | 1 |
| Yu, Y | 1 |
| Tudor, DV | 1 |
| Bâldea, I | 1 |
| Lupu, M | 1 |
| Kacso, T | 1 |
| Kutasi, E | 1 |
| Hopârtean, A | 1 |
| Stretea, R | 1 |
| Gabriela Filip, A | 1 |
| Okamoto, K | 2 |
| Saito, Y | 1 |
| Narumi, K | 1 |
| Furugen, A | 1 |
| Iseki, K | 1 |
| Kobayashi, M | 1 |
| Ragab, FAE | 1 |
| Mohammed, EI | 1 |
| Abdel Jaleel, GA | 1 |
| Selim, AAMAE | 1 |
| Nissan, YM | 1 |
| Wu, H | 4 |
| Xiong, L | 1 |
| Liu, X | 1 |
| Yang, N | 1 |
| Luo, L | 1 |
| Qin, T | 1 |
| Zhu, X | 1 |
| Shen, Z | 1 |
| Jing, H | 1 |
| Chen, J | 2 |
| Goldshtein, H | 1 |
| Muhire, A | 1 |
| Petel Légaré, V | 1 |
| Pushett, A | 1 |
| Rotkopf, R | 1 |
| Shefner, JM | 1 |
| Peterson, RT | 1 |
| Armstrong, GAB | 1 |
| Russek-Blum, N | 1 |
| Zhang, Y | 3 |
| Li, X | 2 |
| Zhou, K | 1 |
| Zhou, M | 1 |
| Xia, K | 1 |
| Xu, Y | 1 |
| Sun, X | 1 |
| Zhu, Y | 2 |
| Cui, C | 1 |
| Deng, C | 1 |
| Santos-Galdiano, M | 2 |
| González-Rodríguez, P | 1 |
| Font-Belmonte, E | 2 |
| Ugidos, IF | 2 |
| Anuncibay-Soto, B | 2 |
| Pérez-Rodríguez, D | 2 |
| Fernández-López, A | 2 |
| Craft, RM | 1 |
| Hewitt, KA | 1 |
| Britch, SC | 1 |
| Huang, Z | 1 |
| Jiang, J | 1 |
| Ye, Y | 1 |
| Gan, C | 1 |
| Su, W | 1 |
| Abou-El-Naga, IF | 1 |
| El-Temsahy, MM | 1 |
| Mogahed, NMFH | 1 |
| Sheta, E | 1 |
| Makled, S | 1 |
| Ibrahim, EI | 1 |
| Na, HS | 2 |
| Kwon, JY | 2 |
| Lee, SH | 3 |
| Woo, JS | 1 |
| Jung, K | 2 |
| Cho, KH | 2 |
| Choi, JW | 1 |
| Lee, DH | 1 |
| Kim, SJ | 3 |
| Tso, MK | 1 |
| Turgeon, P | 1 |
| Bosche, B | 1 |
| Lee, CK | 1 |
| Nie, T | 1 |
| D'Abbondanza, J | 1 |
| Ai, J | 1 |
| Marsden, PA | 1 |
| Macdonald, RL | 1 |
| Gowayed, MA | 1 |
| Abdel-Bary, A | 1 |
| El-Tahan, RA | 1 |
| Siddique, R | 1 |
| Muhammad, F | 1 |
| Aslam, B | 1 |
| Faisal, MN | 1 |
| Ekor, M | 1 |
| Owusu Agyei, PE | 1 |
| Obese, E | 1 |
| Biney, RP | 1 |
| Henneh, IT | 1 |
| Antwi-Adjei, M | 1 |
| Yahaya, ES | 1 |
| Amoakohene, G | 1 |
| Akakpo, PK | 1 |
| Mosaad, SM | 2 |
| Zaitone, SA | 2 |
| Ibrahim, A | 1 |
| El-Baz, AA | 2 |
| Abo-Elmatty, DM | 2 |
| Moustafa, YM | 2 |
| Chang, CC | 1 |
| Lee, WS | 1 |
| Hsieh, HG | 1 |
| Chuang, CL | 1 |
| Lee, FY | 1 |
| Lee, SD | 1 |
| Mei, F | 1 |
| Wang, JG | 1 |
| Chen, ZJ | 1 |
| Yuan, ZL | 1 |
| Neog, MK | 1 |
| Joshua Pragasam, S | 1 |
| Krishnan, M | 1 |
| Rasool, M | 1 |
| Montilla-García, Á | 1 |
| Tejada, MÁ | 1 |
| Perazzoli, G | 1 |
| Entrena, JM | 1 |
| Portillo-Salido, E | 1 |
| Fernández-Segura, E | 1 |
| Cañizares, FJ | 1 |
| Cobos, EJ | 1 |
| Drmic, D | 1 |
| Kolenc, D | 1 |
| Ilic, S | 1 |
| Bauk, L | 1 |
| Sever, M | 1 |
| Zenko Sever, A | 1 |
| Luetic, K | 1 |
| Suran, J | 1 |
| Seiwerth, S | 1 |
| Sikiric, P | 1 |
| Jeong, JW | 1 |
| Lee, HH | 1 |
| Kim, J | 2 |
| Choi, EO | 1 |
| Hwang-Bo, H | 1 |
| Kim, HJ | 1 |
| Kim, MY | 1 |
| Ahn, KI | 1 |
| Kim, GY | 1 |
| Lee, KW | 1 |
| Kim, KY | 1 |
| Kim, SG | 2 |
| Hong, SH | 1 |
| Park, C | 1 |
| Cha, HJ | 1 |
| Choi, YH | 1 |
| Yellepeddi, VK | 1 |
| Radhakrishnan, J | 1 |
| Radhakrishnan, R | 1 |
| Jeong, DH | 1 |
| Ullah, HMA | 1 |
| Goo, MJ | 1 |
| Ghim, SG | 1 |
| Hong, IH | 1 |
| Kim, AY | 1 |
| Jeon, SM | 1 |
| Choi, MS | 1 |
| Elfadl, AK | 1 |
| Chung, MJ | 1 |
| Lee, EJ | 1 |
| Kim, YD | 1 |
| Kim, JH | 1 |
| Kim, SY | 1 |
| Jeong, KS | 1 |
| Mhillaj, E | 1 |
| Morgese, MG | 1 |
| Tucci, P | 1 |
| Furiano, A | 1 |
| Luongo, L | 1 |
| Bove, M | 1 |
| Maione, S | 1 |
| Cuomo, V | 1 |
| Schiavone, S | 1 |
| Trabace, L | 1 |
| Li, L | 1 |
| Yi, J | 1 |
| Liu, H | 2 |
| Lei, H | 1 |
| Ibrahim, MA | 1 |
| Abdelzaher, WY | 1 |
| Rofaeil, RR | 1 |
| Abdelwahab, S | 1 |
| Reijnders, D | 1 |
| Liu, CC | 1 |
| Xu, X | 4 |
| Zhao, AM | 1 |
| Olson, KN | 1 |
| Butler, SD | 1 |
| Douglas, NC | 1 |
| Sones, JL | 1 |
| Silva, RS | 1 |
| Kido, LA | 2 |
| Vendramini-Costa, DB | 1 |
| Pilli, RA | 2 |
| Alboni, S | 1 |
| Benatti, C | 1 |
| Capone, G | 1 |
| Tascedda, F | 1 |
| Brunello, N | 1 |
| Chu, TH | 1 |
| Chan, HH | 1 |
| Hu, TH | 1 |
| Wang, EM | 1 |
| Ma, YL | 1 |
| Huang, SC | 1 |
| Wu, JC | 1 |
| Chang, YC | 1 |
| Weng, WT | 1 |
| Wen, ZH | 1 |
| Wu, DC | 2 |
| Chen, YA | 1 |
| Tai, MH | 1 |
| Cokelaere, SM | 1 |
| Plomp, SGM | 1 |
| de Boef, E | 1 |
| de Leeuw, M | 1 |
| Bool, S | 1 |
| van de Lest, CHA | 1 |
| van Weeren, PR | 1 |
| Korthagen, NM | 1 |
| Harris, TR | 1 |
| Kodani, S | 1 |
| Rand, AA | 1 |
| Yang, J | 2 |
| Imai, DM | 1 |
| Hammock, BD | 1 |
| Chang, CW | 1 |
| Yeh, CN | 1 |
| Chung, YH | 1 |
| Tien, SW | 1 |
| Chen, TW | 1 |
| Farn, SS | 1 |
| Huang, YC | 1 |
| Yu, CS | 1 |
| Tellegen, AR | 3 |
| Rudnik-Jansen, I | 2 |
| Pouran, B | 1 |
| de Visser, HM | 1 |
| Weinans, HH | 1 |
| Thomas, RE | 1 |
| Kik, MJL | 1 |
| Grinwis, GCM | 1 |
| Thies, JC | 2 |
| Woike, N | 2 |
| Mihov, G | 2 |
| Emans, PJ | 1 |
| Meij, BP | 3 |
| Creemers, LB | 3 |
| Tryfonidou, MA | 3 |
| Kurita, M | 1 |
| Yamaguchi, H | 1 |
| Kotera, T | 1 |
| Oka, M | 1 |
| Kalangi, SK | 1 |
| Swarnakar, NK | 1 |
| Sathyavathi, R | 1 |
| Narayana Rao, D | 1 |
| Jain, S | 1 |
| Reddanna, P | 1 |
| Beukers, M | 1 |
| Miranda-Bedate, A | 1 |
| Bach, FC | 1 |
| de Jong, W | 1 |
| Al-Wabli, R | 1 |
| Fouad, M | 1 |
| El-Haggar, R | 1 |
| Lee, CY | 1 |
| Shin, DY | 1 |
| Pérez-García, CC | 1 |
| Sakurai, Y | 1 |
| Fujita, M | 1 |
| Kawasaki, S | 1 |
| Sanaki, T | 1 |
| Yoshioka, T | 1 |
| Higashino, K | 1 |
| Tofukuji, S | 1 |
| Yoneda, S | 1 |
| Takahashi, T | 2 |
| Koda, K | 1 |
| Asaki, T | 1 |
| Hasegawa, M | 1 |
| Morioka, Y | 2 |
| Ren, SX | 1 |
| Zhan, B | 1 |
| Lin, Y | 4 |
| Ma, DS | 1 |
| Yan, H | 2 |
| Garabadu, D | 1 |
| Kumar, V | 1 |
| Zheng, Y | 1 |
| Comaills, V | 1 |
| Burr, R | 1 |
| Boulay, G | 1 |
| Miyamoto, DT | 1 |
| Wittner, BS | 1 |
| Emmons, E | 1 |
| Sil, S | 1 |
| Koulopoulos, MW | 1 |
| Broderick, KT | 1 |
| Tai, E | 1 |
| Rengarajan, S | 1 |
| Kulkarni, AS | 1 |
| Shioda, T | 1 |
| Wu, CL | 1 |
| Ramaswamy, S | 1 |
| Ting, DT | 1 |
| Toner, M | 1 |
| Rivera, MN | 1 |
| Maheswaran, S | 1 |
| Haber, DA | 1 |
| Ferreira, CL | 1 |
| Andersen, ML | 1 |
| Saleem, M | 1 |
| Deal, B | 1 |
| Nehl, E | 1 |
| Pollock, JA | 1 |
| Zhang, K | 1 |
| Zhang, S | 1 |
| Yu, B | 1 |
| Liu, F | 1 |
| Cui, Z | 1 |
| Jin, D | 1 |
| Bai, X | 1 |
| Fan, LW | 1 |
| Kaizaki, A | 1 |
| Tien, LT | 1 |
| Pang, Y | 1 |
| Tanaka, S | 1 |
| Numazawa, S | 1 |
| Bhatt, AJ | 1 |
| Cai, Z | 1 |
| Farooq, F | 1 |
| Abadía-Molina, F | 1 |
| MacKenzie, D | 1 |
| Hadwen, J | 1 |
| Shamim, F | 1 |
| O'Reilly, S | 1 |
| Holcik, M | 1 |
| MacKenzie, A | 1 |
| Yaseen, S | 1 |
| Ovais, S | 1 |
| Bashir, R | 1 |
| Rathore, P | 1 |
| Samim, M | 1 |
| Singh, S | 2 |
| Nair, V | 1 |
| Udd, L | 2 |
| Gao, Y | 1 |
| Ristimäki, AP | 2 |
| Mäkelä, TP | 2 |
| Nakamura, M | 1 |
| Matsui, H | 1 |
| Takahashi, S | 1 |
| Murayama, SY | 1 |
| Suzuki, H | 1 |
| Tsuchimoto, K | 1 |
| Gao, JH | 2 |
| Wen, SL | 2 |
| Yang, WJ | 2 |
| Lu, YY | 2 |
| Huang, ZY | 2 |
| Liu, ZX | 2 |
| Tang, CW | 2 |
| Ji, B | 1 |
| Kumata, K | 1 |
| Onoe, H | 1 |
| Kaneko, H | 1 |
| Zhang, MR | 1 |
| Seki, C | 1 |
| Ono, M | 1 |
| Shukuri, M | 1 |
| Tokunaga, M | 1 |
| Minamihisamatsu, T | 1 |
| Suhara, T | 1 |
| Higuchi, M | 1 |
| Cheng, Q | 1 |
| Li, N | 2 |
| Chen, M | 1 |
| Zheng, J | 1 |
| Qian, Z | 1 |
| Wang, X | 2 |
| Huang, C | 1 |
| Xu, S | 1 |
| Shi, G | 1 |
| Stepanovic-Petrovic, RM | 1 |
| Micov, AM | 1 |
| Tomic, MA | 1 |
| Kovacevic, JM | 1 |
| Boškovic, BD | 1 |
| Maciel, IS | 1 |
| Silva, RB | 1 |
| Morrone, FB | 1 |
| Calixto, JB | 3 |
| Campos, MM | 2 |
| Short, SS | 1 |
| Castle, SL | 1 |
| Fernandez, GE | 1 |
| Smiley, N | 1 |
| Zobel, M | 1 |
| Pontarelli, EM | 1 |
| Papillon, SC | 1 |
| Grishin, AV | 2 |
| Ford, HR | 2 |
| Setia, S | 1 |
| Nehru, B | 1 |
| Sanyal, SN | 1 |
| Zhang, H | 2 |
| Tian, M | 1 |
| Xiu, C | 1 |
| Tang, G | 1 |
| Di Penta, A | 1 |
| Chiba, A | 1 |
| Alloza, I | 1 |
| Wyssenbach, A | 1 |
| Yamamura, T | 1 |
| Villoslada, P | 1 |
| Miyake, S | 1 |
| Vandenbroeck, K | 1 |
| Funahashi, Y | 1 |
| O'Malley, KJ | 1 |
| Kawamorita, N | 1 |
| Tyagi, P | 1 |
| DeFranco, DB | 1 |
| Takahashi, R | 1 |
| Gotoh, M | 1 |
| Wang, Z | 3 |
| Yoshimura, N | 1 |
| Toma, H | 1 |
| Shah, R | 1 |
| Kompella, UB | 1 |
| Vooturi, SK | 1 |
| Sheng, J | 1 |
| Santiago, RM | 1 |
| Barbiero, J | 1 |
| Martynhak, BJ | 1 |
| Boschen, SL | 1 |
| da Silva, LM | 1 |
| Werner, MF | 1 |
| Da Cunha, C | 1 |
| Andreatini, R | 1 |
| Lima, MM | 1 |
| Vital, MA | 1 |
| Sterzik, A | 1 |
| Paprottka, PM | 1 |
| Zengel, P | 1 |
| Hirner, H | 1 |
| Roßpunt, S | 1 |
| Eschbach, R | 1 |
| Moser, M | 1 |
| Havla, L | 1 |
| Ingrisch, M | 1 |
| Mack, B | 1 |
| Reiser, MF | 1 |
| Nikolaou, K | 1 |
| Cyran, CC | 1 |
| Xiao, H | 1 |
| Xue, F | 1 |
| Shi, W | 1 |
| Zhao, H | 2 |
| Ahmed, S | 1 |
| Gul, S | 1 |
| Gul, H | 1 |
| Zia-Ul-Haq, M | 1 |
| Ercisli, S | 1 |
| Zavitsanou, K | 1 |
| Lim, CK | 1 |
| Purves-Tyson, T | 1 |
| Karl, T | 1 |
| Kassiou, M | 1 |
| Banister, SD | 1 |
| Guillemin, GJ | 1 |
| Weickert, CS | 1 |
| Wong, TY | 1 |
| Lin, SM | 1 |
| Chan, FL | 1 |
| Chen, S | 1 |
| Leung, LK | 1 |
| Ho, VW | 1 |
| Hamilton, MJ | 1 |
| Dang, NH | 1 |
| Hsu, BE | 1 |
| Adomat, HH | 1 |
| Guns, ES | 1 |
| Weljie, A | 1 |
| Samudio, I | 1 |
| Bennewith, KL | 1 |
| Krystal, G | 1 |
| Silva, CR | 1 |
| Wentz, AP | 1 |
| Paim, GR | 1 |
| Correa, MS | 1 |
| Prudente, AS | 1 |
| Otuki, MF | 1 |
| Ferreira, J | 2 |
| Daikoku, T | 1 |
| Terakawa, J | 1 |
| Hossain, MM | 1 |
| Yoshie, M | 1 |
| Cappelletti, M | 1 |
| Yang, P | 1 |
| Ellenson, LH | 1 |
| Dey, SK | 1 |
| Lyons, TR | 2 |
| Borges, VF | 2 |
| Betts, CB | 1 |
| Guo, Q | 1 |
| Kapoor, P | 1 |
| Martinson, HA | 1 |
| Jindal, S | 1 |
| Schedin, P | 2 |
| Fomenko, I | 1 |
| Sklyarov, A | 1 |
| Bondarchuk, T | 1 |
| Biletska, L | 1 |
| Panasyuk, N | 1 |
| Wallace, JL | 4 |
| Panahifar, A | 1 |
| Jaremko, JL | 1 |
| Tessier, AG | 1 |
| Lambert, RG | 1 |
| Maksymowych, WP | 1 |
| Fallone, BG | 1 |
| Doschak, MR | 1 |
| Jiang, M | 2 |
| Bi, Y | 2 |
| Han, M | 2 |
| Lan, W | 1 |
| Jin, X | 1 |
| Wang, B | 1 |
| Chen, X | 3 |
| Lai, X | 1 |
| Li, Z | 2 |
| Xu, J | 2 |
| El-Mas, MM | 1 |
| Helmy, MW | 1 |
| Ali, RM | 1 |
| El-Gowelli, HM | 1 |
| Wirrig, EE | 1 |
| Gomez, MV | 1 |
| Hinton, RB | 1 |
| Yutzey, KE | 1 |
| Zhu, CZ | 1 |
| Bannon, AW | 1 |
| Joshi, SK | 2 |
| Guzmán-Hernández, EA | 1 |
| Villalobos-Molina, R | 1 |
| Sánchez-Mendoza, MA | 1 |
| Del Valle-Mondragón, L | 1 |
| Pastelín-Hernández, G | 1 |
| Ibarra-Barajas, M | 1 |
| Li, B | 1 |
| Su, K | 1 |
| Yang, G | 1 |
| Feng, Y | 1 |
| Xia, L | 1 |
| Yin, S | 1 |
| Kim, JS | 1 |
| Ahmadinia, K | 1 |
| Hamilton, JL | 1 |
| Andrews, S | 1 |
| Haralampus, CA | 1 |
| Xiao, G | 1 |
| Sohn, HM | 1 |
| You, JW | 1 |
| Seo, YS | 1 |
| Stein, GS | 1 |
| Im, HJ | 1 |
| Abdelgawad, MA | 1 |
| Elshemy, HA | 1 |
| Alsayed, SS | 1 |
| Kamel, G | 1 |
| Patel, SK | 1 |
| Beaino, W | 1 |
| Anderson, CJ | 1 |
| Costa-Nunes, JP | 1 |
| Cline, BH | 1 |
| Araújo-Correia, M | 1 |
| Valença, A | 1 |
| Markova, N | 1 |
| Dolgov, O | 1 |
| Kubatiev, A | 1 |
| Yeritsyan, N | 1 |
| Steinbusch, HW | 2 |
| Strekalova, T | 1 |
| Qureshi, RA | 1 |
| Tian, Y | 1 |
| McDonald, MK | 1 |
| Capasso, KE | 1 |
| Douglas, SR | 1 |
| Gao, R | 1 |
| Orlova, IA | 1 |
| Barrett, JE | 1 |
| Ajit, SK | 1 |
| Sacan, A | 1 |
| Liu, N | 1 |
| Chen, L | 2 |
| Cai, N | 1 |
| Margulis, K | 1 |
| Neofytou, EA | 1 |
| Beygui, RE | 1 |
| Zare, RN | 1 |
| Willems, N | 1 |
| Yang, HY | 1 |
| Langelaan, ML | 1 |
| Grinwis, GC | 1 |
| Kranenburg, HJ | 1 |
| Riemers, FM | 1 |
| Plomp, SG | 1 |
| Craenmehr, EG | 1 |
| Dhert, WJ | 1 |
| Papen-Botterhuis, NE | 1 |
| Liu, S | 1 |
| Saloustros, E | 1 |
| Berthon, A | 1 |
| Starost, MF | 1 |
| Sahut-Barnola, I | 1 |
| Salpea, P | 1 |
| Szarek, E | 1 |
| Faucz, FR | 1 |
| Martinez, A | 1 |
| Stratakis, CA | 1 |
| Matsuda, H | 1 |
| Hosono, K | 2 |
| Tsuru, S | 1 |
| Kurashige, C | 1 |
| Sekiguchi, K | 1 |
| Akira, S | 1 |
| Uematsu, S | 1 |
| Okamoto, H | 2 |
| Majima, M | 2 |
| Vahidi, R | 1 |
| Safi, S | 1 |
| Farsinejad, A | 1 |
| Panahi, N | 1 |
| Laux-Biehlmann, A | 1 |
| Boyken, J | 1 |
| Dahllöf, H | 1 |
| Schmidt, N | 1 |
| Zollner, TM | 1 |
| Nagel, J | 1 |
| Gould, SA | 1 |
| Doods, H | 1 |
| Lamla, T | 1 |
| Pekcec, A | 2 |
| Sauce, R | 1 |
| Macedo, AB | 1 |
| Minatel, E | 1 |
| Costa, DB | 1 |
| Carvalho, JE | 1 |
| Cagnon, VH | 1 |
| Evageliou, NF | 1 |
| Haber, M | 1 |
| Vu, A | 1 |
| Laetsch, TW | 1 |
| Murray, J | 1 |
| Gamble, LD | 1 |
| Cheng, NC | 1 |
| Liu, K | 1 |
| Reese, M | 1 |
| Corrigan, KA | 1 |
| Ziegler, DS | 1 |
| Webber, H | 1 |
| Hayes, CS | 1 |
| Pawel, B | 1 |
| Marshall, GM | 1 |
| Gilmour, SK | 1 |
| Norris, MD | 1 |
| Hogarty, MD | 1 |
| Suri, A | 1 |
| Sheng, X | 1 |
| Schuler, KM | 1 |
| Zhong, Y | 1 |
| Han, X | 1 |
| Jones, HM | 1 |
| Gehrig, PA | 1 |
| Zhou, C | 1 |
| Bae-Jump, VL | 1 |
| DiBattista, AM | 1 |
| Dumanis, SB | 1 |
| Newman, J | 1 |
| Rebeck, GW | 1 |
| Arendt-Nielsen, L | 1 |
| Harris, S | 1 |
| Whiteside, GT | 2 |
| Hummel, M | 1 |
| Knappenberger, T | 1 |
| O'Keefe, S | 1 |
| Kapil, R | 1 |
| Kyle, D | 1 |
| Kumar, G | 1 |
| Goldberg, SN | 1 |
| Velez, E | 1 |
| Gourevitch, S | 1 |
| Galun, E | 1 |
| Ahmed, M | 1 |
| Toriyama, S | 1 |
| Horinaka, M | 1 |
| Yasuda, S | 1 |
| Taniguchi, T | 1 |
| Aono, Y | 1 |
| Takamura, T | 1 |
| Miki, T | 1 |
| Ukimura, O | 1 |
| Sakai, T | 1 |
| El-Sayed El-Sisi, A | 1 |
| Sokkar, SS | 1 |
| El-Sayed El-Sayad, M | 1 |
| Sayed Ramadan, E | 1 |
| Osman, EY | 1 |
| Sadhu, SS | 1 |
| Averineni, RK | 1 |
| Seefeldt, T | 1 |
| Yang, Y | 2 |
| Guan, X | 1 |
| Koselny, K | 1 |
| Green, J | 2 |
| DiDone, L | 1 |
| Halterman, JP | 1 |
| Fothergill, AW | 1 |
| Wiederhold, NP | 1 |
| Patterson, TF | 1 |
| Cushion, MT | 1 |
| Rappelye, C | 1 |
| Wellington, M | 1 |
| Krysan, DJ | 1 |
| Sung, MW | 2 |
| Lee, DY | 1 |
| Park, SW | 1 |
| Oh, SM | 1 |
| Choi, JJ | 1 |
| Shin, ES | 1 |
| Kwon, SK | 1 |
| Ahn, SH | 1 |
| Kim, YH | 1 |
| Ozawa, J | 1 |
| Kaneguchi, A | 1 |
| Tanaka, R | 1 |
| Kito, N | 1 |
| Moriyama, H | 1 |
| Gowda, R | 1 |
| Kardos, G | 1 |
| Sharma, A | 1 |
| Robertson, GP | 1 |
| Ozer, EK | 1 |
| Goktas, MT | 1 |
| Kilinc, I | 1 |
| Bariskaner, H | 1 |
| Ugurluoglu, C | 1 |
| Iskit, AB | 1 |
| Peck, Y | 1 |
| Leom, LT | 1 |
| Low, PFP | 1 |
| Wang, DA | 1 |
| Zhang, Z | 1 |
| Yu, S | 1 |
| Cheng, D | 1 |
| Han, C | 1 |
| Lv, H | 1 |
| Ye, F | 1 |
| Ahmed, AA | 1 |
| Panda, BP | 1 |
| Kohli, K | 1 |
| Fahim, M | 1 |
| Dubey, K | 1 |
| Campillo, N | 1 |
| Torres, M | 1 |
| Vilaseca, A | 1 |
| Nonaka, PN | 1 |
| Gozal, D | 1 |
| Roca-Ferrer, J | 1 |
| Picado, C | 1 |
| Montserrat, JM | 1 |
| Farré, R | 1 |
| Navajas, D | 1 |
| Almendros, I | 1 |
| Colby, JK | 1 |
| Klein, RD | 1 |
| McArthur, MJ | 1 |
| Conti, CJ | 1 |
| Kiguchi, K | 1 |
| Kawamoto, T | 1 |
| Riggs, PK | 1 |
| Pavone, AI | 1 |
| Sawicki, J | 1 |
| Fischer, SM | 2 |
| Dabhi, JK | 1 |
| Solanki, JK | 1 |
| Mehta, A | 1 |
| Moghaddamt, HF | 1 |
| Ardestani, MS | 2 |
| Saffari, M | 1 |
| Navidpour, L | 1 |
| Shafiee, A | 1 |
| Rahmim, A | 1 |
| Herbenick, MA | 1 |
| Sprott, D | 1 |
| Stills, H | 1 |
| Lawless, M | 1 |
| Huh, JE | 2 |
| Baek, YH | 2 |
| Kim, YJ | 1 |
| Lee, JD | 2 |
| Choi, DY | 1 |
| Park, DS | 3 |
| Vardar-Sengul, S | 1 |
| Buduneli, E | 2 |
| Turkoglu, O | 1 |
| Buduneli, N | 2 |
| Atilla, G | 2 |
| Wahlgren, J | 1 |
| Sorsa, T | 1 |
| Baylas, H | 2 |
| Zhang, HJ | 1 |
| Sun, RP | 1 |
| Lei, GF | 1 |
| Yang, L | 1 |
| Liu, CX | 1 |
| Moghaddam, HF | 1 |
| Hemmati, A | 1 |
| Nazari, Z | 1 |
| Mehrab, H | 1 |
| Abid, KM | 1 |
| Song, C | 1 |
| Manku, M | 1 |
| Medina, D | 2 |
| Kittrell, F | 1 |
| Hill, J | 2 |
| Hilsenbeck, SG | 1 |
| Bissonette, R | 1 |
| Brown, PH | 2 |
| Abba, MC | 1 |
| Levy, CC | 1 |
| Gaddis, S | 1 |
| Kittrell, FS | 1 |
| Bissonnette, RP | 1 |
| Aldaz, CM | 1 |
| Woditschka, S | 2 |
| Haag, JD | 3 |
| Sullivan, R | 1 |
| Gould, MN | 3 |
| Queiroz-Junior, CM | 1 |
| Pacheco, CM | 1 |
| Maltos, KL | 1 |
| Caliari, MV | 1 |
| Duarte, ID | 2 |
| Francischi, JN | 3 |
| Fegn, L | 1 |
| Hsieh, PS | 2 |
| Jin, JS | 1 |
| Chiang, CF | 2 |
| Chan, PC | 1 |
| Chen, CH | 2 |
| Shih, KC | 1 |
| Enami, Y | 1 |
| Bandi, S | 1 |
| Kapoor, S | 1 |
| Krohn, N | 1 |
| Joseph, B | 1 |
| Gupta, S | 2 |
| Koul, A | 1 |
| Tanwar, L | 1 |
| Arora, N | 1 |
| Foreman, JE | 1 |
| Sorg, JM | 1 |
| McGinnis, KS | 1 |
| Rigas, B | 1 |
| Williams, JL | 1 |
| Clapper, ML | 2 |
| Gonzalez, FJ | 1 |
| Peters, JM | 1 |
| Lada-Moldovan, L | 1 |
| Kaloustian, S | 1 |
| Bah, TM | 1 |
| Girard, SA | 1 |
| Déry, MA | 1 |
| Rousseau, G | 1 |
| Haagen, J | 1 |
| Krohn, H | 1 |
| Röllig, S | 1 |
| Schmidt, M | 1 |
| Wolfram, K | 1 |
| Dörr, W | 1 |
| Das Roy, L | 1 |
| Pathangey, LB | 2 |
| Tinder, TL | 3 |
| Schettini, JL | 1 |
| Gruber, HE | 1 |
| Mukherjee, P | 3 |
| Jenkins, BG | 1 |
| Carreras, I | 1 |
| Kaymakcalan, S | 1 |
| Cormier, K | 1 |
| Kowall, NW | 1 |
| Dedeoglu, A | 1 |
| Boyce-Rustay, JM | 1 |
| Zhong, C | 1 |
| Kohnken, R | 1 |
| Baker, SJ | 2 |
| Simler, GH | 1 |
| Wensink, EJ | 1 |
| Decker, MW | 1 |
| Honore, P | 2 |
| Kuo, CH | 1 |
| Hu, HM | 1 |
| Tsai, PY | 1 |
| Wu, IC | 1 |
| Yang, SF | 1 |
| Chang, LL | 1 |
| Wang, JY | 1 |
| Jan, CM | 1 |
| Wang, WM | 1 |
| Shibazaki, T | 1 |
| Yozgatian, JH | 1 |
| Zeredo, JL | 1 |
| Gonzales, C | 1 |
| Hotokezaka, H | 1 |
| Koga, Y | 1 |
| Yoshida, N | 1 |
| Yanni, SE | 1 |
| Clark, ML | 1 |
| Yang, R | 1 |
| Bingaman, DP | 1 |
| Penn, JS | 1 |
| Zhou, JY | 1 |
| Zhou, DF | 1 |
| Liu, YH | 1 |
| Wang, W | 2 |
| Wei, F | 1 |
| Schrage, YM | 1 |
| Machado, I | 1 |
| Meijer, D | 1 |
| Briaire-de Bruijn, I | 1 |
| van den Akker, BE | 1 |
| Taminiau, AH | 1 |
| Kalinski, T | 1 |
| Llombart-Bosch, A | 1 |
| Bovée, JV | 1 |
| Ueno, T | 1 |
| Suzuki, T | 1 |
| Oikawa, A | 1 |
| Kosaka, Y | 1 |
| Amano, H | 1 |
| Kitasato, H | 1 |
| Toda, M | 1 |
| Hayashi, I | 1 |
| Kato, T | 1 |
| Ito, Y | 1 |
| Sugimoto, Y | 1 |
| Narumiya, S | 1 |
| Lu, KC | 1 |
| Tran-Thanh, D | 1 |
| Buttars, S | 1 |
| Wen, Y | 1 |
| Wilson, C | 1 |
| Done, SJ | 1 |
| Li, WZ | 1 |
| Wang, XY | 1 |
| Li, ZG | 1 |
| Zhang, JH | 1 |
| Ding, YQ | 1 |
| Sohrabi, M | 1 |
| Soleimani, J | 1 |
| Roshangar, L | 1 |
| Vatansever, S | 1 |
| Arbabi, F | 1 |
| Khaki, AA | 1 |
| Abbasi, MM | 1 |
| Dustar, Y | 1 |
| Javadzadeh, Y | 1 |
| Coon, KD | 1 |
| Inge, LJ | 1 |
| Swetel, K | 1 |
| Felton, V | 1 |
| Stafford, P | 1 |
| Bremner, RM | 3 |
| Stan, SD | 1 |
| Singh, SV | 1 |
| Brand, RE | 1 |
| Correa, JD | 1 |
| Paiva-Lima, P | 1 |
| Rezende, RM | 1 |
| Dos Reis, WG | 1 |
| Ferreira-Alves, DL | 1 |
| Bakhle, YS | 1 |
| Peterson, JD | 1 |
| Labranche, TP | 1 |
| Vasquez, KO | 1 |
| Kossodo, S | 1 |
| Melton, M | 1 |
| Rader, R | 1 |
| Listello, JT | 1 |
| Abrams, MA | 1 |
| Misko, TP | 1 |
| Chávez, E | 1 |
| Segovia, J | 1 |
| Shibayama, M | 1 |
| Tsutsumi, V | 1 |
| Vergara, P | 1 |
| Castro-Sánchez, L | 1 |
| Salazar, EP | 1 |
| Moreno, MG | 1 |
| Muriel, P | 1 |
| Schlichtiger, J | 1 |
| Bartmann, H | 1 |
| Winter, P | 1 |
| Fuest, C | 1 |
| Soerensen, J | 1 |
| Potschka, H | 1 |
| Kang, M | 1 |
| Jung, I | 1 |
| Hur, J | 1 |
| Kim, SH | 1 |
| Lee, JH | 1 |
| Kang, JY | 1 |
| Jung, KC | 1 |
| Kim, KS | 2 |
| Yoo, MC | 2 |
| Cho, YB | 1 |
| Lau, WK | 1 |
| Lau, YM | 1 |
| Zhang, HQ | 1 |
| Wong, SC | 1 |
| Bian, ZX | 1 |
| Veltman, JD | 1 |
| Lambers, ME | 1 |
| van Nimwegen, M | 1 |
| Hendriks, RW | 1 |
| Hoogsteden, HC | 1 |
| Aerts, JG | 1 |
| Hegmans, JP | 1 |
| Robich, MP | 1 |
| Chu, LM | 1 |
| Feng, J | 1 |
| Burgess, TA | 1 |
| Laham, RJ | 1 |
| Bianchi, C | 1 |
| Sellke, FW | 1 |
| Xiao, J | 1 |
| Lv, Y | 1 |
| Liu, Y | 1 |
| Yang, H | 1 |
| Zhao, L | 1 |
| Jiang, B | 1 |
| Zeng, Y | 1 |
| Li, MJ | 1 |
| Xu, JY | 1 |
| Zhang, YN | 1 |
| Wang, QJ | 1 |
| Sun, NY | 1 |
| Lu, T | 1 |
| Wu, XM | 1 |
| Ferland, CE | 1 |
| Laverty, S | 1 |
| Beaudry, F | 1 |
| Vachon, P | 1 |
| Zandieh, A | 1 |
| Maleki, F | 1 |
| Hajimirzabeigi, A | 1 |
| Zandieh, B | 1 |
| Khalilzadeh, O | 1 |
| Dehpour, AR | 1 |
| Gendy, AS | 1 |
| Lipskar, A | 1 |
| Glick, RD | 1 |
| Steinberg, BM | 1 |
| Edelman, M | 1 |
| Soffer, SZ | 1 |
| Liu, FX | 1 |
| Wang, WH | 1 |
| Gao, PP | 1 |
| Li, DQ | 1 |
| Zhong, J | 1 |
| Wu, XL | 1 |
| Chen, Q | 1 |
| Peng, H | 1 |
| Liu, SQ | 1 |
| Lauder, SN | 1 |
| Taylor, PR | 1 |
| Clark, SR | 1 |
| Evans, RL | 1 |
| Hindley, JP | 1 |
| Smart, K | 1 |
| Leach, H | 1 |
| Kidd, EJ | 1 |
| Broadley, KJ | 1 |
| Jones, SA | 1 |
| Wise, MP | 1 |
| Godkin, AJ | 1 |
| O'Donnell, V | 1 |
| Gallimore, AM | 1 |
| Zhang, Q | 1 |
| Qiu, J | 1 |
| Li, H | 1 |
| Lu, Y | 1 |
| Gu, Y | 1 |
| Hao, CM | 1 |
| Vaddady, PK | 1 |
| Mehrotra, N | 1 |
| Yates, CR | 1 |
| Moore, BM | 1 |
| Meibohm, B | 1 |
| Sereno, J | 1 |
| Parada, B | 1 |
| Reis, F | 1 |
| Cunha, FX | 1 |
| Teixeira-Lemos, E | 1 |
| Garrido, P | 1 |
| Pinto, R | 1 |
| Rocha-Pereira, P | 1 |
| Neto, P | 1 |
| Ruivo, J | 1 |
| Rodrigues-Santos, P | 1 |
| Nunes, S | 1 |
| Mota, A | 1 |
| Figueiredo, A | 1 |
| Teixeira, F | 1 |
| Fan, X | 1 |
| Takahashi-Yanaga, F | 1 |
| Morimoto, S | 1 |
| Zhan, DY | 1 |
| Igawa, K | 1 |
| Tomooka, K | 1 |
| Sasaguri, T | 1 |
| Gravitz, L | 1 |
| Roan, JN | 1 |
| Tsai, YC | 1 |
| Chen, IW | 1 |
| Chang, SW | 1 |
| Huang, CC | 1 |
| Lam, CF | 1 |
| Ou, YS | 1 |
| Tan, C | 2 |
| An, H | 2 |
| Jiang, DM | 1 |
| Quan, ZX | 1 |
| Tang, K | 2 |
| Luo, XJ | 1 |
| Olivares, C | 1 |
| Ricci, A | 1 |
| Bilotas, M | 1 |
| Barañao, RI | 1 |
| Meresman, G | 1 |
| Syer, S | 1 |
| Denou, E | 1 |
| de Palma, G | 1 |
| Vong, L | 1 |
| McKnight, W | 1 |
| Jury, J | 1 |
| Bolla, M | 1 |
| Bercik, P | 1 |
| Collins, SM | 1 |
| Verdu, E | 1 |
| Ongini, E | 1 |
| Gandhi, SR | 1 |
| Tiwari, AK | 1 |
| Kunte, DP | 1 |
| De la Cruz, MA | 1 |
| Stypula, Y | 1 |
| Gibson, T | 1 |
| Brasky, J | 1 |
| Backman, V | 1 |
| Wali, RK | 1 |
| Roy, HK | 1 |
| O'Brien, J | 1 |
| Conklin, MW | 1 |
| Keely, PJ | 1 |
| Eliceiri, KW | 1 |
| Marusyk, A | 1 |
| Tan, AC | 1 |
| Suddek, GM | 1 |
| El-Kenawi, AE | 1 |
| Abdel-Aziz, A | 1 |
| El-Kashef, HA | 1 |
| González-Mateo, GT | 1 |
| Aroeira, LS | 1 |
| López-Cabrera, M | 1 |
| Ruiz-Ortega, M | 1 |
| Ortiz, A | 1 |
| Selgas, R | 1 |
| Salvadori, MG | 1 |
| Banderó, CR | 1 |
| Jesse, AC | 1 |
| Gomes, AT | 1 |
| Rambo, LM | 1 |
| Bueno, LM | 1 |
| Bortoluzzi, VT | 1 |
| Oliveira, MS | 1 |
| Mello, CF | 1 |
| Scharovsky, OG | 1 |
| Matar, P | 1 |
| Rozados, VR | 1 |
| Rico, MJ | 1 |
| Zacarías Fluck, MF | 1 |
| Mainetti, LE | 1 |
| Fernández Zenóbi, MV | 1 |
| Roggero, EA | 1 |
| Gervasoni, SI | 1 |
| Rossa, A | 1 |
| Perroud, HA | 1 |
| Sánchez, AM | 1 |
| Celoria, GC | 1 |
| Font, MT | 1 |
| Choudry, HA | 1 |
| Mavanur, A | 1 |
| O'Malley, ME | 1 |
| Zeh, HJ | 1 |
| Guo, Z | 1 |
| Lubet, RA | 5 |
| McCormick, DL | 1 |
| Pereira, MA | 1 |
| Chang, WC | 1 |
| Steele, VE | 2 |
| Juliana, MM | 1 |
| Grubbs, CJ | 2 |
| Xu, T | 1 |
| Wang, NS | 1 |
| Fu, LL | 1 |
| Ye, CY | 1 |
| Yu, SQ | 1 |
| Mei, CL | 1 |
| Su, CL | 1 |
| Yuan, DW | 1 |
| Chiang, LL | 1 |
| Lee, HL | 1 |
| Chen, KH | 1 |
| Ou, Y | 1 |
| Jiang, D | 1 |
| Quan, Z | 1 |
| Luo, X | 1 |
| Su, LW | 1 |
| Zhu, YF | 1 |
| Lang, HJ | 1 |
| Zhang, F | 1 |
| Zhou, YA | 1 |
| Liang, XH | 1 |
| Wang, YJ | 1 |
| Hill, R | 1 |
| Tran, LM | 1 |
| Dry, S | 1 |
| Calvopina, JH | 1 |
| Garcia, A | 1 |
| Kim, C | 1 |
| Donahue, TR | 1 |
| Herschman, HR | 1 |
| Borre, Y | 1 |
| Lemstra, S | 1 |
| Westphal, KG | 1 |
| Morgan, ME | 1 |
| Olivier, B | 1 |
| Oosting, RS | 1 |
| Mukherjee, K | 1 |
| Gitlin, JM | 1 |
| Loftin, CD | 1 |
| Upadhyay, J | 1 |
| Rajagovindan, R | 1 |
| Hart, M | 1 |
| Chandran, P | 1 |
| Hooker, BA | 1 |
| Cassar, S | 1 |
| Mikusa, JP | 1 |
| Tovcimak, A | 1 |
| Wald, MJ | 1 |
| Bannon, A | 1 |
| Medema, JK | 1 |
| Beaver, J | 1 |
| Kamath, RV | 1 |
| Fox, GB | 1 |
| Day, M | 1 |
| Cetin, S | 1 |
| Tobey, AB | 1 |
| Sandulache, VC | 1 |
| Yang, T | 1 |
| Barsic, M | 1 |
| Dohar, JE | 1 |
| Hebda, PA | 1 |
| Mani, BK | 1 |
| O'Dowd, J | 1 |
| Kumar, L | 1 |
| Brueggemann, LI | 1 |
| Ross, M | 1 |
| Byron, KL | 1 |
| Zhang, B | 1 |
| Gao, X | 1 |
| Wang, F | 1 |
| Shen, G | 1 |
| Sang, Y | 1 |
| Li, M | 1 |
| Zhao, J | 1 |
| Wei, Y | 1 |
| Muller-Decker, K | 1 |
| Neufang, G | 1 |
| Berger, I | 1 |
| Neumann, M | 1 |
| Marks, F | 1 |
| Furstenberger, G | 1 |
| Long, J | 1 |
| Lewis, S | 1 |
| Kuklo, T | 1 |
| Riew, KD | 1 |
| Drachman, DB | 1 |
| Frank, K | 1 |
| Dykes-Hoberg, M | 1 |
| Teismann, P | 1 |
| Almer, G | 1 |
| Przedborski, S | 1 |
| Rothstein, JD | 1 |
| Fuentes, CF | 1 |
| Shapshay, SM | 1 |
| Hegazi, RA | 1 |
| Mady, HH | 1 |
| Melhem, MF | 1 |
| Sepulveda, AR | 1 |
| Mohi, M | 1 |
| Kandil, HM | 1 |
| Wilgus, TA | 1 |
| Koki, AT | 2 |
| Zweifel, BS | 3 |
| Rubal, PA | 1 |
| Oberyszyn, TM | 1 |
| Forslund, C | 1 |
| Bylander, B | 1 |
| Aspenberg, P | 1 |
| Diperna, CA | 1 |
| Bart, RD | 2 |
| Sievers, EM | 2 |
| Ma, Y | 1 |
| Starnes, VA | 2 |
| Gessell-Lee, DL | 1 |
| Popov, VL | 1 |
| Boldogh, I | 1 |
| Olano, JP | 1 |
| Peterson, JW | 1 |
| Harrison, J | 1 |
| Boulet, J | 1 |
| Mark, L | 1 |
| Pearson, M | 1 |
| Gottshall, S | 1 |
| Walker, K | 3 |
| Lanza-Jacoby, S | 2 |
| Miller, S | 1 |
| Flynn, J | 1 |
| Gallatig, K | 1 |
| Daskalakis, C | 1 |
| Masferrer, JL | 3 |
| Sembhi, H | 1 |
| Russo, IH | 1 |
| Schäfers, M | 1 |
| Marziniak, M | 1 |
| Sorkin, LS | 1 |
| Yaksh, TL | 1 |
| Sommer, C | 1 |
| Davis, TW | 1 |
| O'Neal, JM | 1 |
| Pagel, MD | 1 |
| Mehta, PP | 1 |
| Heuvelman, DM | 1 |
| Schilling, G | 1 |
| Savonenko, AV | 1 |
| Coonfield, ML | 1 |
| Morton, JL | 1 |
| Vorovich, E | 1 |
| Gale, A | 1 |
| Neslon, C | 1 |
| Chan, N | 1 |
| Eaton, M | 1 |
| Fromholt, D | 1 |
| Ross, CA | 1 |
| Borchelt, DR | 1 |
| Vajja, BN | 1 |
| Juluri, S | 1 |
| Kumari, M | 1 |
| Kole, L | 1 |
| Chakrabarti, R | 1 |
| Joshi, VD | 1 |
| Rodrigues-Filho, R | 1 |
| Santos, AR | 1 |
| Bertelli, JA | 1 |
| Singh, VP | 1 |
| Patil, CS | 1 |
| Jain, NK | 1 |
| Kulkarni, SK | 1 |
| Chu, AJ | 1 |
| Chou, TH | 1 |
| Chen, BD | 1 |
| Veiga, AP | 1 |
| Avila, MN | 1 |
| da Motta, PG | 1 |
| Tatsuo, MA | 1 |
| Wu, N | 1 |
| Sood, S | 2 |
| Jin, Z | 1 |
| Beer, DG | 1 |
| Giordano, TJ | 1 |
| Shih, WC | 1 |
| Yang, CS | 2 |
| Katajisto, P | 1 |
| Rossi, DJ | 1 |
| Lepistö, A | 1 |
| Lahesmaa, AM | 1 |
| Ylikorkala, A | 1 |
| Järvinen, HJ | 1 |
| Umar, A | 1 |
| Boisseau, M | 1 |
| Yusup, A | 1 |
| Upur, H | 1 |
| Bégaud, B | 1 |
| Moore, N | 1 |
| Basu, GD | 2 |
| Lagioia, M | 1 |
| Gendler, SJ | 1 |
| Narayanan, BA | 2 |
| Narayanan, NK | 2 |
| Pittman, B | 1 |
| Reddy, BS | 2 |
| Vanchieri, C | 1 |
| Lu, YM | 1 |
| Dong, XY | 1 |
| Fong, LY | 1 |
| Jiang, Y | 1 |
| Farber, JL | 1 |
| Efstathiou, JA | 1 |
| Sampson, DA | 1 |
| Levine, Z | 1 |
| Rohan, RM | 1 |
| Zurakowski, D | 2 |
| Folkman, J | 2 |
| D'Amato, RJ | 1 |
| Rupnick, MA | 1 |
| Roh, JL | 1 |
| Kim, KH | 1 |
| Fang, M | 1 |
| Sun, Z | 1 |
| Graepler, F | 1 |
| Gregor, M | 1 |
| Lauer, UM | 1 |
| Pomonis, JD | 1 |
| Boulet, JM | 1 |
| Gottshall, SL | 1 |
| Phillips, S | 1 |
| Sellers, R | 1 |
| Bunton, T | 1 |
| Vardar, S | 1 |
| Berdeli, AH | 1 |
| Gebhardt, BM | 1 |
| Varnell, ED | 1 |
| Kaufman, HE | 1 |
| Backhus, LM | 1 |
| Starnes, M | 1 |
| Castanos, R | 1 |
| Aimbire, F | 1 |
| Albertine, R | 1 |
| de Magalhães, RG | 1 |
| Lopes-Martins, RA | 1 |
| Castro-Faria-Neto, HC | 1 |
| Zângaro, RA | 1 |
| Chavantes, MC | 1 |
| Pacheco, MT | 1 |
| Greene, AK | 1 |
| Alwayn, IP | 1 |
| Nose, V | 1 |
| Flynn, E | 1 |
| Sampson, D | 1 |
| Puder, M | 1 |
| Miwa, K | 1 |
| Oyama, K | 1 |
| Fujimura, T | 1 |
| Tong, CT | 1 |
| Howard, SA | 1 |
| Shah, HR | 1 |
| Van Quill, KR | 1 |
| Lin, ET | 1 |
| Grossniklaus, HE | 1 |
| O'Brien, JM | 1 |
| Alhan, E | 1 |
| Kalyoncu, NI | 1 |
| Ercin, C | 1 |
| Kural, BV | 1 |
| Pttman, B | 1 |
| Mastbergen, SC | 1 |
| Marijnissen, AC | 1 |
| Vianen, ME | 1 |
| Zoer, B | 1 |
| van Roermund, PM | 1 |
| Bijlsma, JW | 1 |
| Lafeber, FP | 1 |
| Jeong, BC | 1 |
| Park, MY | 1 |
| Kwak, C | 1 |
| Kim, BS | 1 |
| Kim, JI | 1 |
| Kim, HH | 1 |
| Potoka, DA | 1 |
| Hackam, DJ | 1 |
| Upperman, JS | 1 |
| Boyle, P | 1 |
| Zamora, R | 1 |
| Levin, VA | 1 |
| Giglio, P | 1 |
| Puduvalli, VK | 1 |
| Jochec, J | 1 |
| Groves, MD | 1 |
| Yung, WK | 1 |
| Hess, K | 1 |
| Mernitz, H | 1 |
| Smith, DE | 1 |
| Zhu, AX | 1 |
| Wang, XD | 1 |
| Hui, AY | 1 |
| Leung, WK | 1 |
| Chan, HL | 1 |
| Chan, FK | 1 |
| Go, MY | 1 |
| Chan, KK | 1 |
| Tang, BD | 1 |
| Chu, ES | 1 |
| Sung, JJ | 1 |
| Chichorro, JG | 1 |
| Zampronio, AR | 1 |
| Souza, GE | 1 |
| Rae, GA | 1 |
| Melnikova, T | 1 |
| Savonenko, A | 1 |
| Wang, Q | 1 |
| Liang, X | 1 |
| Hand, T | 1 |
| Wu, L | 1 |
| Kaufmann, WE | 1 |
| Vehmas, A | 1 |
| Andreasson, KI | 1 |
| Jung, KH | 2 |
| Chu, K | 2 |
| Lee, ST | 2 |
| Sinn, DI | 2 |
| Kim, JM | 2 |
| Park, DK | 2 |
| Lee, JJ | 1 |
| Kim, SU | 1 |
| Kim, M | 2 |
| Lee, SK | 1 |
| Roh, JK | 2 |
| Cahill, RA | 1 |
| Bradley, JM | 1 |
| Tu, T | 1 |
| Hattrup, CL | 1 |
| Pockaj, BA | 1 |
| Song, EC | 1 |
| Kardosh, A | 1 |
| Su, YS | 1 |
| Schonthal, AH | 1 |
| Chen, TC | 1 |
| Timmers, L | 1 |
| Sluijter, JP | 1 |
| Verlaan, CW | 1 |
| Steendijk, P | 1 |
| Cramer, MJ | 1 |
| Emons, M | 1 |
| Strijder, C | 1 |
| Gründeman, PF | 1 |
| Sze, SK | 1 |
| Hua, L | 1 |
| Piek, JJ | 1 |
| Borst, C | 1 |
| Pasterkamp, G | 1 |
| de Kleijn, DP | 1 |
| Shpitz, B | 1 |
| Giladi, N | 1 |
| Sagiv, E | 1 |
| Lev-Ari, S | 1 |
| Liberman, E | 1 |
| Kazanov, D | 1 |
| Arber, N | 1 |
| Chen, JD | 1 |
| Tessier, J | 1 |
| Green, C | 1 |
| Padgett, D | 1 |
| Zhao, W | 1 |
| Schwartz, L | 1 |
| Hughes, M | 1 |
| Hewlett, E | 1 |
| Javle, MM | 1 |
| Cao, S | 1 |
| Durrani, FA | 1 |
| Pendyala, L | 1 |
| Lawrence, DD | 1 |
| Smith, PF | 1 |
| Creaven, PJ | 1 |
| Noel, DC | 1 |
| Iyer, RV | 1 |
| Rustum, YM | 1 |
| Fournier, LS | 1 |
| Novikov, V | 1 |
| Lucidi, V | 1 |
| Fu, Y | 1 |
| Miller, T | 1 |
| Floyd, E | 1 |
| Shames, DM | 1 |
| Brasch, RC | 1 |
| Simon, AM | 1 |
| O'Connor, JP | 1 |
| Futagami, S | 1 |
| Suzuki, K | 1 |
| Hiratsuka, T | 1 |
| Shindo, T | 1 |
| Hamamoto, T | 1 |
| Tatsuguchi, A | 1 |
| Ueki, N | 1 |
| Shinji, Y | 1 |
| Kusunoki, M | 1 |
| Wada, K | 1 |
| Miyake, K | 1 |
| Gudis, K | 1 |
| Tsukui, T | 1 |
| Sakamoto, C | 1 |
| Amos-Landgraf, JM | 1 |
| Kwong, LN | 1 |
| Kendziorski, CM | 1 |
| Reichelderfer, M | 1 |
| Torrealba, J | 1 |
| Weichert, J | 1 |
| Chen, KS | 1 |
| Waller, JL | 1 |
| Dove, WF | 1 |
| Sarotra, P | 1 |
| Aggarwal, R | 1 |
| Dutta, N | 1 |
| Agnihotri, N | 1 |
| Okayama, M | 1 |
| Hayashi, S | 1 |
| Aoi, Y | 1 |
| Nishio, H | 1 |
| Kato, S | 1 |
| Takeuchi, K | 1 |
| Park, EK | 1 |
| Rhee, HI | 1 |
| Jung, HS | 1 |
| Ju, SM | 1 |
| Lee, YA | 1 |
| Hong, SJ | 1 |
| Yang, HI | 1 |
| Sato, H | 1 |
| Bolli, R | 1 |
| Rokosh, GD | 1 |
| Bi, Q | 1 |
| Dai, S | 1 |
| Shirk, G | 1 |
| Tang, XL | 1 |
| Myint, AM | 1 |
| Goeghegan, L | 1 |
| Luchtman, D | 1 |
| Kim, YK | 1 |
| Leonard, BE | 1 |
| Okumura, T | 1 |
| Sakakibara, A | 1 |
| Murata, Y | 1 |
| Kita, Y | 1 |
| Queiroz, AF | 1 |
| Moura, RM | 1 |
| Ribeiro, JK | 1 |
| Lyra, IL | 1 |
| Cunha, DC | 1 |
| Santos, EA | 1 |
| de-Sales, MP | 1 |
| Vegeler, RC | 1 |
| Yip-Schneider, MT | 1 |
| Ralstin, M | 1 |
| Crooks, PA | 1 |
| Neelakantan, S | 1 |
| Nakshatri, H | 1 |
| Sweeney, CJ | 1 |
| Schmidt, CM | 1 |
| Jacob, S | 1 |
| Laury-Kleintop, L | 1 |
| Rapuano, BE | 1 |
| Boursiquot, R | 1 |
| Tomin, E | 1 |
| Macdonald, DE | 1 |
| Maddula, S | 1 |
| Raghavan, D | 1 |
| Lane, JM | 1 |
| Helfet, DL | 1 |
| Knight, S | 1 |
| Johns, EJ | 1 |
| Bertucci, AM | 1 |
| Smith, KA | 1 |
| Xu, L | 1 |
| Datta, SK | 1 |
| Inglis, JJ | 1 |
| Notley, CA | 1 |
| Essex, D | 1 |
| Wilson, AW | 1 |
| Feldmann, M | 1 |
| Anand, P | 1 |
| Williams, R | 1 |
| Lozano, H | 1 |
| Wu, D | 1 |
| Bassuk, J | 1 |
| Aria, J | 1 |
| Kurlansky, P | 1 |
| Lamas, GA | 1 |
| Adams, JA | 1 |
| Fromm, RE | 1 |
| Varon, J | 1 |
| Sharma, B | 1 |
| Singh, N | 1 |
| Singh, M | 1 |
| Mau, B | 1 |
| Costa, R | 1 |
| Marotta, DM | 1 |
| Manjavachi, MN | 1 |
| Fernandes, ES | 1 |
| Lima-Garcia, JF | 1 |
| Paszcuk, AF | 1 |
| Quintão, NL | 1 |
| Juliano, L | 1 |
| Brain, SD | 1 |
| Dash, PK | 1 |
| Mach, SA | 1 |
| Moore, AN | 1 |
| Laudanno, OM | 1 |
| Cesolari, JA | 1 |
| Esnarriaga, J | 1 |
| Rista, L | 1 |
| Piombo, G | 1 |
| Maglione, C | 1 |
| Aramberry, LJ | 1 |
| Sambrano, JS | 1 |
| Godoy, A | 1 |
| Rocaspana, A | 1 |
| Ajuebor, MN | 1 |
| Singh, A | 1 |
| Tibble, JA | 1 |
| Sigthorsson, G | 1 |
| Foster, R | 1 |
| Bjarnason, I | 1 |
| Jacoby, RF | 1 |
| Seibert, K | 2 |
| Cole, CE | 1 |
| Kelloff, G | 1 |
| Leahy, KM | 1 |
| Kelloff, GJ | 1 |
| Hill, DL | 1 |
| Niederberger, E | 1 |
| Tegeder, I | 1 |
| Vetter, G | 1 |
| Schmidtko, A | 1 |
| Schmidt, H | 1 |
| Euchenhofer, C | 1 |
| Bräutigam, L | 1 |
| Grösch, S | 1 |
| Geisslinger, G | 1 |
| Hennan, JK | 1 |
| Huang, J | 1 |
| Barrett, TD | 1 |
| Driscoll, EM | 1 |
| Willens, DE | 1 |
| Park, AM | 1 |
| Crofford, LJ | 1 |
| Lucchesi, BR | 1 |
| Reilly, TP | 1 |
| Brady, JN | 1 |
| Marchick, MR | 1 |
| Bourdi, M | 1 |
| George, JW | 1 |
| Radonovich, MF | 1 |
| Pise-Masison, CA | 1 |
| Pohl, LR | 1 |
| Jantzen, PT | 1 |
| Connor, KE | 1 |
| DiCarlo, G | 1 |
| Wenk, GL | 1 |
| Rojiani, AM | 1 |
| Coppola, D | 1 |
| Morgan, D | 1 |
| Gordon, MN | 1 |
| Medhurst, SJ | 1 |
| Bowes, M | 1 |
| Kidd, BL | 1 |
| Glatt, M | 1 |
| Muller, M | 1 |
| Hattenberger, M | 1 |
| Vaxelaire, J | 1 |
| O'Reilly, T | 1 |
| Wotherspoon, G | 1 |
| Winter, J | 1 |
| Urban, L | 1 |
| Cuzzocrea, S | 1 |
| Mazzon, E | 1 |
| Sautebin, L | 1 |
| Dugo, L | 1 |
| Serraino, I | 1 |
| De Sarro, A | 1 |
| Caputi, AP | 1 |
| Orengo, IF | 1 |
| Gerguis, J | 1 |
| Phillips, R | 1 |
| Guevara, A | 1 |
| Lewis, AT | 1 |
| Black, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pain Modulation in RA - Influence of Adalimumab. A Randomized, Placebo-controlled Study Using Functional Magnetic Resonance Imaging (PARADE)[NCT01197144] | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for celecoxib and Disease Models, Animal
| Article | Year |
|---|---|
Systematic review and meta-analysis of studies in which burrowing behaviour was assessed in rodent models of disease-associated persistent pain.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Disease M | 2022 |
COX-2 as a potential biomarker and therapeutic target in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Celecoxib; Clinical Tria | 2020 |
Chemoprevention strategies for pancreatic cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2010 |
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinogens | 2004 |
[Anti-angiogenic therapy for gastrointestinal tumours].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2005 |
3 trials available for celecoxib and Disease Models, Animal
| Article | Year |
|---|---|
A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile.
Topics: Adolescent; Adult; Aminopyridines; Animals; Capsaicin; Celecoxib; Cross-Over Studies; Cyclooxygenase | 2016 |
Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Di | 2006 |
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celeco | 2007 |
331 other studies available for celecoxib and Disease Models, Animal
| Article | Year |
|---|---|
2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors.
Topics: Animals; Arthritis, Experimental; Combinatorial Chemistry Techniques; Cyclooxygenase 1; Cyclooxygena | 2001 |
Naphthalene derivatives: A new series of selective cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2001 |
Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Carrageenan; Cyclooxygenase 2; Cycl | 2008 |
Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeic Acids; Celecoxib; Cy | 2008 |
Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cell Line; Cyclooxygenase 2 Inhibitors; Disease Model | 2009 |
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Di | 2009 |
Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Crystallography, X-Ray; Cyclooxygenas | 2011 |
Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.
Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Computer Simulation; Cyclooxygenase 1; Cyclooxygen | 2011 |
Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2.
Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Cyclooxygenase 2 Inhibitors; Disease Models, Anima | 2012 |
Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Cell Proliferation; Disease Models, Animal; D | 2012 |
Potent and orally efficacious benzothiazole amides as TRPV1 antagonists.
Topics: Amides; Animals; Benzothiazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; I | 2012 |
3D QSAR studies based in silico screening of 4,5,6-triphenyl-1,2,3,4-tetrahydropyrimidine analogs for anti-inflammatory activity.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Design; Edema; Female; Male; Mode | 2014 |
Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Car | 2014 |
Synthesis and evaluation of pyrazolines bearing benzothiazole as anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Benzothiazoles; Binding Sites; Carrageenan; Catalytic Domain; Cel | 2014 |
Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice.
Topics: Animals; Celecoxib; Disease Models, Animal; Edema; Hydrocarbons, Fluorinated; Hyperalgesia; Male; Mi | 2015 |
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Carrageenan; Cyclooxygenase Inhi | 2017 |
Synthesis and evaluations of selective COX-2 inhibitory effects: Benzo[d]thiazol analogs.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 | 2020 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Synthesis and computational studies of novel fused pyrimidinones as a promising scaffold with analgesic, anti-inflammatory and COX inhibitory potential.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Behavior, Animal; Cyclooxygenase 1; Cyclooxygenase 2; | 2021 |
Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cyclooxygenase 2; Disease Models, Animal; Indazol | 2022 |
Low-dose cyclooxygenase-2 (COX-2) inhibitor celecoxib plays a protective role in the rat model of neonatal necrotizing enterocolitis.
Topics: Animals; Animals, Newborn; Apoptosis; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal | 2021 |
Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress.
Topics: Animals; Antioxidants; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Management; | 2021 |
Post-traumatic osteoarthritis progression is diminished by early mechanical unloading and anti-inflammatory treatment in mice.
Topics: Animals; Anterior Cruciate Ligament Injuries; Anti-Inflammatory Agents, Non-Steroidal; Cathepsins; C | 2021 |
Vitronectin-derived bioactive peptide prevents spondyloarthritis by modulating Th17/Treg imbalance in mice with curdlan-induced spondyloarthritis.
Topics: Animals; beta-Glucans; Celecoxib; Cytokines; Disease Models, Animal; Disease Progression; Female; Ge | 2022 |
Celecoxib in the treatment of orofacial pain and discomfort in rats subjected to a dental occlusal interference model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Dental Occlusion; Dis | 2022 |
Selenocoxib-3, a novel anti-inflammatory therapeutic effectively resolves colitis.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis; Coli | 2023 |
High-dose Tiger-Gian formula protects the knee joint from surgically induced osteoarthritis in rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Disease Models, Animal; Knee Joint; Male; Osteo | 2023 |
High-dose Tiger-Gian formula protects the knee joint from surgically induced osteoarthritis in rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Disease Models, Animal; Knee Joint; Male; Osteo | 2023 |
High-dose Tiger-Gian formula protects the knee joint from surgically induced osteoarthritis in rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Disease Models, Animal; Knee Joint; Male; Osteo | 2023 |
High-dose Tiger-Gian formula protects the knee joint from surgically induced osteoarthritis in rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Disease Models, Animal; Knee Joint; Male; Osteo | 2023 |
High-dose Tiger-Gian formula protects the knee joint from surgically induced osteoarthritis in rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Disease Models, Animal; Knee Joint; Male; Osteo | 2023 |
High-dose Tiger-Gian formula protects the knee joint from surgically induced osteoarthritis in rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Disease Models, Animal; Knee Joint; Male; Osteo | 2023 |
High-dose Tiger-Gian formula protects the knee joint from surgically induced osteoarthritis in rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Disease Models, Animal; Knee Joint; Male; Osteo | 2023 |
High-dose Tiger-Gian formula protects the knee joint from surgically induced osteoarthritis in rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Disease Models, Animal; Knee Joint; Male; Osteo | 2023 |
High-dose Tiger-Gian formula protects the knee joint from surgically induced osteoarthritis in rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Disease Models, Animal; Knee Joint; Male; Osteo | 2023 |
Low-dose celecoxib-loaded PCL fibers reverse intervertebral disc degeneration by up-regulating CHSY3 expression.
Topics: Animals; Celecoxib; Dinoprostone; Disease Models, Animal; Intervertebral Disc Degeneration; Mice; Ra | 2023 |
Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Disease Models, Animal; Humans; Male; Mice; Mice, Inbred C57BL | 2023 |
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate
Topics: Adoptive Transfer; Aerosols; Animals; Bacterial Load; Celecoxib; Cell Differentiation; Cyclooxygenas | 2019 |
Inhibition of COX-2 Pathway as a Potential Prophylaxis Against Arthrofibrogenesis in a Rabbit Model of Joint Contracture.
Topics: Animals; Arthroplasty, Replacement, Knee; Biomechanical Phenomena; Celecoxib; Collagen; Contracture; | 2019 |
Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Depression; Disease M | 2019 |
Neuroprotective effects of melatonin and celecoxib against ethanol-induced neurodegeneration: a computational and pharmacological approach.
Topics: Animals; Celecoxib; Computational Biology; Disease Models, Animal; Ethanol; Injections, Intraperiton | 2019 |
PEGylated Lipova E120 liposomes loaded with celecoxib:
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Celecoxib; Disease Models, Animal; Humans; | 2019 |
COX-2 inhibition rescues depression-like behaviors via suppressing glial activation, oxidative stress and neuronal apoptosis in rats.
Topics: Animals; Antidepressive Agents; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2019 |
Role of anti-inflammatory interventions in high-fat-diet-induced obesity.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cytokines; Diet, High-Fat; Disease Models, Animal; Fat | 2020 |
Coadministration of lithium and celecoxib reverses manic-like behavior and decreases oxidative stress in a dopaminergic model of mania induced in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimanic Agents; Behavior, Animal; Bipolar Disord | 2019 |
Celecoxib cannot inhibit the progression of initiated traumatic heterotopic ossification.
Topics: Achilles Tendon; Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease M | 2019 |
Effect of celecoxib on protein expression of FAK and Cx43 in DMBA induced rat tongue carcinoma cells.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxi | 2019 |
Impacts of a Specific Cyclooxygenase-2 Inhibitor on Pressure Overload-Induced Myocardial Hypertrophy in Rats.
Topics: Animals; C-Reactive Protein; Cardiomegaly; Celecoxib; Cyclooxygenase 2 Inhibitors; Diet; Dinoproston | 2019 |
Combatting joint pain and inflammation by dual inhibition of monoacylglycerol lipase and cyclooxygenase-2 in a rat model of osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthralgia; Benzodioxoles; Celecoxib; Cyclooxygenase 2 Inhibitors | 2020 |
Antinociceptive and anti-inflammatory effects of 4-(arylchalcogenyl)-1H-pyrazoles containing selenium or sulfur.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Celecoxib; Disease Models, Animal; Dose-Response Rela | 2020 |
Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Topics: Animals; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2 I | 2020 |
Sex Differences Revealed in a Mouse CFA Inflammation Model with Macrophage Targeted Nanotheranostics.
Topics: Adjuvants, Immunologic; Administration, Intravenous; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxyg | 2020 |
Reduction of arthrofibrosis utilizing a collagen membrane drug-eluting scaffold with celecoxib and subcutaneous injections with ketotifen.
Topics: Animals; Celecoxib; Contracture; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Delivery | 2020 |
Effect of celecoxib in treatment of burn-induced hypermetabolism.
Topics: Adipose Tissue, Brown; Administration, Oral; Animals; Burns; Celecoxib; Cyclooxygenase 2; Cyclooxyge | 2020 |
Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autophagy; Celecoxib; Cell Line; Cisplatin; Cytopr | 2020 |
Synthesis of Hydroxybenzofuranyl-pyrazolyl and Hydroxyphenyl-pyrazolyl Chalcones and Their Corresponding Pyrazoline Derivatives as COX Inhibitors, Anti-inflammatory and Gastroprotective Agents.
Topics: Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Binding Sites; Catalytic Domain; Celecoxib; | 2020 |
Quercetin Downregulates Cyclooxygenase-2 Expression and HIF-1
Topics: Angiogenesis Inhibitors; Animals; Aortic Aneurysm, Abdominal; Celecoxib; Cyclooxygenase 2 Inhibitors | 2020 |
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Celecoxib; Ciprofloxacin; Dis | 2020 |
Influence of Experimental Autoimmune Prostatitis on Sexual Function and the Anti-inflammatory Efficacy of Celecoxib in a Rat Model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Celecoxib; Depression; Diseas | 2020 |
Celecoxib-Dependent Neuroprotection in a Rat Model of Transient Middle Cerebral Artery Occlusion (tMCAO) Involves Modifications in Unfolded Protein Response (UPR) and Proteasome.
Topics: Animals; Apoptosis; Autophagy; Biomarkers; Brain Ischemia; Celecoxib; Disease Models, Animal; eIF-2 | 2021 |
Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, Animal; Dos | 2021 |
Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats.
Topics: Animals; Apoptosis; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Hepatic S | 2021 |
Effect of celecoxib against different developmental stages of experimental Schistosoma mansoni infection.
Topics: Administration, Oral; Animals; Anthelmintics; Apoptosis; Celecoxib; Disease Models, Animal; Female; | 2021 |
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway.
Topics: Animals; Arthritis, Experimental; Celecoxib; Chondrocytes; Diabetes Mellitus, Type 2; Disease Models | 2021 |
Gene expression profiling of brain endothelial cells after experimental subarachnoid haemorrhage.
Topics: Animals; Blood-Brain Barrier; Brain Injuries; Brain Ischemia; Celecoxib; Cyclooxygenase 2; Cyclooxyg | 2021 |
The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation.
Topics: Acetic Acid; Analgesia; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dic | 2021 |
Inhibition of cyclooxygenase-2 enhanced intestinal epithelial homeostasis via suppressing β-catenin signalling pathway in experimental liver fibrosis.
Topics: Animals; beta Catenin; Celecoxib; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease | 2021 |
Characterization and in vivo evaluation of nanoformulations in FCA induced rheumatoid arthritis in rats.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Catechols; Celecoxib; Di | 2021 |
Celecoxib exhibits therapeutic potential in experimental model of hyperlipidaemia.
Topics: Animals; Atorvastatin; Celecoxib; Cholesterol; Coconut Oil; Disease Models, Animal; Hyperlipidemias; | 2021 |
Celecoxib aggravates cardiac apoptosis in L-NAME-induced pressure overload model in rats: Immunohistochemical determination of cardiac caspase-3, Mcl-1, Bax and Bcl-2.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blood Pressure; Cardiomegaly; Caspase 3; Celecoxib; | 2017 |
Selective cyclooxygenase inhibition by SC-560 improves hepatopulmonary syndrome in cirrhotic rats.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Disease Models, Animal; Down-Regula | 2017 |
Effects of epoxyeicosatrienoic acids (EETs) on retinal macular degeneration in rat models.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Celecoxib; Choroidal Neovascularization; Cyclooxygenase 2 Inhi | 2017 |
p-Coumaric acid, a dietary polyphenol ameliorates inflammation and curtails cartilage and bone erosion in the rheumatoid arthritis rat model.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone Resorption; Cartilage; Celecoxib; Coum | 2017 |
Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia.
Topics: Acetaminophen; Analgesics; Animals; Arthritis; Celecoxib; Disease Models, Animal; Diterpenes; Female | 2017 |
Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME.
Topics: Animals; Anti-Ulcer Agents; Antidotes; Arginine; Brain; Celecoxib; Chemical and Drug Induced Liver I | 2017 |
Mori Folium water extract alleviates articular cartilage damages and inflammatory responses in monosodium iodoacetate‑induced osteoarthritis rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Dinoprostone; Disease Models, Animal; Down-Regu | 2017 |
Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Celecoxib; | 2018 |
Effects of oral glucosamine hydrochloride and mucopolysaccharide protein in a rabbit model of osteoarthritis.
Topics: Administration, Oral; Animals; Anterior Cruciate Ligament; Apoptosis; Cartilage, Articular; Celecoxi | 2018 |
Celecoxib Prevents Cognitive Impairment and Neuroinflammation in Soluble Amyloid β-treated Rats.
Topics: Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Brain-Derived N | 2018 |
Dose-Effect of Irbesartan on Cyclooxygenase-2 and Matrix Metalloproteinase-9 Expression in Rabbit Atherosclerosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Atheroscle | 2018 |
Efficacy and safety of combined low doses of either diclofenac or celecoxib with gabapentin versus their single high dose in treatment of neuropathic pain in rats.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Diclofenac; D | 2018 |
Celecoxib restores angiogenic factor expression at the maternal-fetal interface in the BPH/5 mouse model of preeclampsia.
Topics: Angiogenesis Inducing Agents; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Anima | 2018 |
Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice.
Topics: Adenocarcinoma; Animals; Celecoxib; Cyclooxygenase 2; Disease Models, Animal; Estrogen Receptor alph | 2018 |
Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Celecoxib; Depression; D | 2018 |
Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Celecoxib; C | 2018 |
Sustained intra-articular release of celecoxib in an equine repeated LPS synovitis model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Celecoxib; Delayed-Action Preparations | 2018 |
Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbon Tetrachloride; Celecoxib; Collagen; Cycloox | 2018 |
Synthesis and evaluation of
Topics: Animals; Celecoxib; Cholangiocarcinoma; Cyclooxygenase 2; Dihydroxyphenylalanine; Disease Models, An | 2018 |
Controlled release of celecoxib inhibits inflammation, bone cysts and osteophyte formation in a preclinical model of osteoarthritis.
Topics: Animals; Anterior Cruciate Ligament; Biocompatible Materials; Bone and Bones; Celecoxib; Cyclooxygen | 2018 |
Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: Effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain.
Topics: Analgesics; Animals; Autoimmune Diseases; Celecoxib; Chemokines; Chronic Pain; Cytokines; Disease Mo | 2018 |
Synthesis, Characterization, and Biodistribution of Quantum Dot-Celecoxib Conjugate in Mouse Paw Edema Model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, Animal; Edema; Magnetic | 2018 |
Intradiscal delivery of celecoxib-loaded microspheres restores intervertebral disc integrity in a preclinical canine model.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Action Preparations; Disease Models, Animal | 2018 |
Synthesis, In-vivo and In-vitro Anti-inflammatory Evaluation of some Novel Coumarin Derivatives.
Topics: Albumins; Animals; Anti-Inflammatory Agents; Celecoxib; Coumarins; Disease Models, Animal; Dose-Resp | 2018 |
Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10.
Topics: Anilides; Animals; Cartilage; Cartilage, Articular; Celecoxib; Chondrocytes; Chondrogenesis; Cytokin | 2018 |
Celecoxib Treatment Improves Neurologic Deficit and Reduces Selective Neuronal Loss and Glial Response in Rats after Transient Middle Cerebral Artery Occlusion.
Topics: Animals; Astrocytes; Celecoxib; Disease Models, Animal; Infarction, Middle Cerebral Artery; Male; Ne | 2018 |
Contribution of synovial macrophages to rat advanced osteoarthritis pain resistant to cyclooxygenase inhibitors.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dinoprostone; Disease | 2019 |
Selenium Nanoparticles Dispersed in Phytochemical Exert Anti-Inflammatory Activity by Modulating Catalase, GPx1, and COX-2 Gene Expression in a Rheumatoid Arthritis Rat Model.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Experimental; Arthritis, Rheumatoid; Cat | 2019 |
Celecoxib potentiates the antianxiety and anticompulsive-like activity of fluoxetine against chronic unpredictable mild stress in experimental animals.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Celecoxib; Compulsive Behavior; Disease Mod | 2019 |
COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.
Topics: Animals; Carcinogenesis; Celecoxib; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygenas | 2019 |
Coadministration of lithium and celecoxib attenuates the behavioral alterations and inflammatory processes induced by amphetamine in an animal model of mania.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimanic Agents; Behavior, | 2019 |
Nanomedicine-driven neuropathic pain relief in a rat model is associated with macrophage polarity and mast cell activation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Polarity; Disease Models, Animal; | 2019 |
Celecoxib inhibits the heterotopic ossification in the rat model with Achilles tenotomy.
Topics: Achilles Tendon; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Male; Ossi | 2013 |
Celecoxib attenuates systemic lipopolysaccharide-induced brain inflammation and white matter injury in the neonatal rats.
Topics: Age Factors; Animals; Animals, Newborn; Brain; Calcium-Binding Proteins; Celecoxib; Cell Death; Cycl | 2013 |
Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation.
Topics: Adolescent; Animals; Brain; Celecoxib; Cells, Cultured; Child; Child, Preschool; Disease Models, Ani | 2013 |
Synthesis and biological evaluation of 4-arylphthalazones bearing benzenesulfonamide as anti-inflammatory and anti-cancer agents.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Benzenesulfonamides; Celecoxib; Cell Line, | 2013 |
N-methylnitrosourea aggravates gastrointestinal polyposis in Lkb1+/- mice.
Topics: AMP-Activated Protein Kinases; Animals; Carcinogenesis; Carcinogens; Celecoxib; Cyclooxygenase 2 Inh | 2013 |
New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib.
Topics: Angiogenesis Inhibitors; Animals; Antibodies; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models | 2014 |
Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Disease Models, Animal; Hypertension, Portal; Kidney; L | 2013 |
Assessment of radioligands for PET imaging of cyclooxygenase-2 in an ischemic neuronal injury model.
Topics: Animals; Antibodies; Brain; Brain Ischemia; Carbon Radioisotopes; Celecoxib; Cyclooxygenase 2; Disea | 2013 |
Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats.
Topics: Animals; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diet, High-Fat; Diseas | 2013 |
Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Ceftriaxone; Ce | 2014 |
Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Brain-Derive | 2013 |
Low doses of celecoxib attenuate gut barrier failure during experimental peritonitis.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Ileum; Intest | 2013 |
Activation of NF-κB: bridging the gap between inflammation and cancer in colitis-mediated colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Celecoxib; Colitis, Ulcerative; Colonic Neoplasms; Cyclooxygenase 2 | 2014 |
Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cancer Vaccines; Celecoxib; Cell Line, T | 2013 |
A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation.
Topics: Animals; Astrocytes; Axons; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Cytokines; Dise | 2013 |
Upregulation of androgen-responsive genes and transforming growth factor-β1 cascade genes in a rat model of non-bacterial prostatic inflammation.
Topics: Androgens; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Mod | 2014 |
The safety, pharmacokinetics, and efficacy of intraocular celecoxib.
Topics: Animals; Aqueous Humor; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Electroretin | 2014 |
Antidepressant-like effect of celecoxib piroxicam in rat models of depression.
Topics: Animals; Antidepressive Agents; Celecoxib; Depression; Disease Models, Animal; Exploratory Behavior; | 2014 |
DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Celecoxib; Combined M | 2015 |
[Effects of selective and non-selective cyclooxygenase 2 inhibitors on heterotopic ossification in rat model with Achilles tenotomy].
Topics: Achilles Tendon; Animals; Bone Morphogenetic Protein 2; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2014 |
Cyclooxygenase-2 inhibition improves antioxidative defense during experimental hypercholesterolemia.
Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Cyclooxygenase 2 Inhibitors; Disease Models, Ani | 2014 |
Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition.
Topics: Animals; Brain; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dizocilpine Maleate; | 2014 |
Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Down-Regulation; Epithelial | 2014 |
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
Topics: Animals; Apoptosis; Aromatase; Aspirin; Body Weight; Breast Neoplasms; Celecoxib; Cell Cycle; Cycloo | 2014 |
A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis.
Topics: Animals; Celecoxib; Diet Therapy; Diet, Carbohydrate-Restricted; Dietary Proteins; Disease Models, A | 2014 |
Antinociceptive effect of 3-(4-fluorophenyl)-5-trifluoromethyl-1H-1-tosylpyrazole. A Celecoxib structural analog in models of pathological pain.
Topics: Analgesics; Animals; Celecoxib; Disease Models, Animal; Male; Mice; Pain; Pyrazoles; Sulfonamides; T | 2014 |
Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma; Celecoxib; Cell Line, | 2014 |
Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.
Topics: Animals; Breast Neoplasms; Celecoxib; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Female | 2014 |
Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Celecoxib; Disease Models, Animal; Epi | 2014 |
Development and reliability of a multi-modality scoring system for evaluation of disease progression in pre-clinical models of osteoarthritis: celecoxib may possess disease-modifying properties.
Topics: Animals; Anterior Cruciate Ligament; Bone Cysts; Bone Marrow Diseases; Cartilage, Articular; Celecox | 2014 |
Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor.
Topics: Anemia; Animals; Antibodies, Monoclonal; Body Weight; Cachexia; Celecoxib; Cell Line, Tumor; Cycloox | 2015 |
Regulated expression of PTPRJ by COX-2/PGE2 axis in endothelial cells.
Topics: Animals; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, | 2014 |
Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway.
Topics: Animals; Blood Vessels; Breast Neoplasms; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxyge | 2015 |
Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclosporine; Cytoprote | 2015 |
COX2 inhibition reduces aortic valve calcification in vivo.
Topics: Aged; Aged, 80 and over; Animals; Aortic Valve; Biomarkers; Calcinosis; Case-Control Studies; Celeco | 2015 |
Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats.
Topics: Adjuvants, Immunologic; Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxy | 2015 |
Early co-expression of cyclooxygenase-2 and renin in the rat kidney cortex contributes to the development of N(G)-nitro-L-arginine methyl ester induced hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Capto | 2015 |
Assessment of the potential ototoxicity of high-dose celecoxib, a selective cyclooxygenase-2 inhibitor, in rats.
Topics: Animals; Auditory Threshold; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Re | 2015 |
Development of an Experimental Animal Model for Lower Back Pain by Percutaneous Injury-Induced Lumbar Facet Joint Osteoarthritis.
Topics: Animals; Celecoxib; Disease Models, Animal; Humans; Low Back Pain; Lumbar Vertebrae; Models, Animal; | 2015 |
Synthesis and anti-inflammatory evaluation of new 1,3,5-triaryl-4,5-dihydro-1H-pyrazole derivatives possessing an aminosulphonyl pharmacophore.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Inf | 2015 |
Theranostic nanoemulsions for macrophage COX-2 inhibition in a murine inflammation model.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Celecoxib; Cell Line; Cell Movemen | 2015 |
Animal Models of Depression and Drug Delivery with Food as an Effective Dosing Method: Evidences from Studies with Celecoxib and Dicholine Succinate.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Celecoxib; Depressive Disorder; Disease Models, An | 2015 |
Circulating microRNA Signatures in Rodent Models of Pain.
Topics: Animals; Celecoxib; Circulating MicroRNA; Disease Models, Animal; Freund's Adjuvant; Gene Expression | 2016 |
Celecoxib attenuates retinal angiogenesis in a mouse model of oxygen-induced retinopathy.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease | 2015 |
Celecoxib Nanoparticles for Therapeutic Angiogenesis.
Topics: Angiogenesis Inducing Agents; Animals; Blood Vessels; Celecoxib; Disease Models, Animal; Humans; Isc | 2015 |
Biocompatibility and intradiscal application of a thermoreversible celecoxib-loaded poly-N-isopropylacrylamide MgFe-layered double hydroxide hydrogel in a canine model.
Topics: Acrylic Resins; Animals; Biocompatible Materials; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyc | 2015 |
Celecoxib reduces glucocorticoids in vitro and in a mouse model with adrenocortical hyperplasia.
Topics: Adrenal Cortex; Animals; Celecoxib; Cushing Syndrome; Disease Models, Animal; Down-Regulation; Femal | 2016 |
Roles of mPGES-1, an inducible prostaglandin E synthase, in enhancement of LPS-induced lymphangiogenesis in a mouse peritonitis model.
Topics: Animals; Celecoxib; Diaphragm; Disease Models, Animal; Glycoproteins; Intramolecular Oxidoreductases | 2015 |
Citrate and celecoxib induce apoptosis and decrease necrosis in synergistic manner in canine mammary tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2015 |
Dynamic weight bearing as a non-reflexive method for the measurement of abdominal pain in mice.
Topics: Abdominal Pain; Aniline Compounds; Animals; Behavior, Animal; Celecoxib; Chronic Pain; Cyclooxygenas | 2016 |
Pharmacological characterization of intraplantar Complete Freund's Adjuvant-induced burrowing deficits.
Topics: Amines; Analgesics; Animals; Antibodies; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; D | 2016 |
Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Celecoxib; Cycl | 2016 |
Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Line | 2016 |
The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.
Topics: Animals; Apoptosis; BRCA1 Protein; Celecoxib; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Prol | 2016 |
Identification and modification of amyloid-independent phenotypes of APOE4 mice.
Topics: Age Factors; Alzheimer Disease; Amyloid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipopr | 2016 |
Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition.
Topics: Animals; Catheter Ablation; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Disease Mode | 2017 |
A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells.
Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Caspases; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell P | 2016 |
Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Celecoxib; Disease Models, Animal; Drug Therapy, Comb | 2016 |
In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dacarbazine; Disease Models, An | 2016 |
The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.
Topics: Animals; Antifungal Agents; Candida; Caspofungin; Celecoxib; Cryptococcosis; Cryptococcus neoformans | 2016 |
Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Celeco | 2017 |
Cyclooxygenase-2 inhibitor celecoxib attenuates joint contracture following immobilization in rat knees.
Topics: Administration, Oral; Animals; Arthritis; Celecoxib; Contracture; Cyclooxygenase 2; Cyclooxygenase 2 | 2016 |
Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygena | 2017 |
Celecoxib administration reduced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ injury in septic rats.
Topics: Animals; Aorta; Aortic Diseases; Celecoxib; Cytokines; Disease Models, Animal; Female; Glutathione; | 2017 |
Establishment of an in vitro three-dimensional model for cartilage damage in rheumatoid arthritis.
Topics: Animals; Apoptosis; Arthritis, Rheumatoid; Cartilage, Articular; Celecoxib; Cell Culture Techniques; | 2018 |
Synthesis and Evaluation of Anti-inflammatory N-Substituted 3,5-Bis(2-(trifluoromethyl)benzylidene)piperidin-4-ones.
Topics: Animals; Anti-Inflammatory Agents; Bone Marrow Cells; Carrageenan; Celecoxib; Cell Survival; Dinopro | 2017 |
Evening primrose oil or forskolin ameliorates celecoxib-enhanced upregulation of tissue factor expression in mice subjected to lipopolysaccharide-induced endotoxemia.
Topics: Animals; Antithrombin III; Blood Coagulation; Celecoxib; Colforsin; Cyclooxygenase 2 Inhibitors; Dis | 2017 |
Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model.
Topics: Animals; Cardiotoxicity; Celecoxib; Disease Models, Animal; Folic Acid; Heart Failure; Male; Random | 2017 |
Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea.
Topics: Animals; Celecoxib; Cell Polarity; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Disease Model | 2017 |
Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Transformation, Neoplastic | 2008 |
Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study.
Topics: Animals; Anti-Inflammatory Agents; Antiparasitic Agents; Aspirin; Atherosclerosis; Celecoxib; Diseas | 2008 |
Dopaminergic but not glutamatergic neurotransmission is increased in the striatum after selective cyclooxygenase-2 inhibition in normal and hemiparkinsonian rats.
Topics: Animals; Celecoxib; Corpus Striatum; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2008 |
Effects of a cyclooxygenase 2 inhibitor on fracture healing in a rat model.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Fracture Healing; Male; Pyraz | 2008 |
Protective effects of butanol fraction from Betula platyphyla var. japonica on cartilage alterations in a rabbit collagenase-induced osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents; Betula; Cartilage, Articular; Celecoxib; Collagenases; Cyclooxyge | 2009 |
The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis.
Topics: Alveolar Bone Loss; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Co | 2008 |
Cyclooxygenase-2 inhibitor inhibits hippocampal synaptic reorganization in pilocarpine-induced status epilepticus rats.
Topics: Animals; Blotting, Western; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models | 2008 |
Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygena | 2007 |
Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment.
Topics: Analysis of Variance; Animals; Celecoxib; Corticosterone; Corticotropin-Releasing Hormone; Cyclooxyg | 2009 |
Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, | 2009 |
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitor | 2009 |
A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Bexarotene; Carcinoma | 2009 |
Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats.
Topics: Alveolar Bone Loss; Animals; Arachidonic Acid; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, | 2009 |
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Topics: Administration, Topical; Analysis of Variance; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxy | 2009 |
COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Animals; Blood Glucose; Body Weight; Celecoxib; Cell Size; | 2009 |
Hepatic stellate cells promote hepatocyte engraftment in rat liver after prostaglandin-endoperoxide synthase inhibition.
Topics: Analysis of Variance; Animals; Blotting, Western; Celecoxib; Cell Survival; Cells, Cultured; Disease | 2009 |
Celecoxib administration exhibits tissue specific effect on 3H-benzo(a)pyrene-DNA adduct formation in cigarette smoke inhaling mice.
Topics: Administration, Oral; Animals; Benzo(a)pyrene; Body Weight; Celecoxib; Cytochrome P-450 Enzyme Syste | 2009 |
Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Blotting, Western; Celecoxib; Coloni | 2009 |
Chronic pretreatment with celecoxib reduces infarct size.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Infusions, Parenteral; Isch | 2009 |
Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies.
Topics: Animals; Antibodies, Monoclonal; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dos | 2009 |
Therapeutic effect of Aralia cordata extracts on cartilage protection in collagenase-induced inflammatory arthritis rabbit model.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Aralia; Arthritis; Cartilage; Caspase 3; Celecoxib; Ch | 2009 |
Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis; Autoimmune Dise | 2009 |
Anti-inflammatory treatment in AD mice protects against neuronal pathology.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroi | 2010 |
Comparison of mechanical allodynia and the affective component of inflammatory pain in rats.
Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Celecoxib; Central Nervous System Agents; Diclo | 2010 |
Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Celecoxib; Cell Proliferation; Cyclooxygenase 2; C | 2009 |
Effect of celecoxib on emotional stress and pain-related behaviors evoked by experimental tooth movement in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Biomechanical Phenomena; Celecox | 2009 |
The effects of nepafenac and amfenac on retinal angiogenesis.
Topics: Analysis of Variance; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Benzeneace | 2010 |
[Study on the mechanism of preventing alcholic liver disease by selective cyclooxygenase 2 inhibitor].
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dise | 2009 |
COX-2 expression in chondrosarcoma: a role for celecoxib treatment?
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Celecoxib; Cell Survival; Chondrosarcoma; Cyclooxyge | 2010 |
Recruited bone marrow cells expressing the EP3 prostaglandin E receptor subtype enhance angiogenesis during chronic inflammation.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2010 |
Suppressive effect of COX2 inhibitor on the progression of adipose inflammation in high-fat-induced obese rats.
Topics: Adiposity; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blood Glucose; Blood Pr | 2010 |
Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, B | 2010 |
Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cell L | 2010 |
The effect of dietary and topical celecoxib on 4-nitroquinoline-1-oxide-induced lingual epithelium alternations in rat.
Topics: 4-Nitroquinoline-1-oxide; Administration, Topical; Analysis of Variance; Animals; Celecoxib; Cycloox | 2009 |
Genomic characterization of the inflammatory response initiated by surgical intervention and the effect of perioperative cyclooxygenase 2 blockade.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal | 2010 |
Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Response | 2010 |
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cathepsins; Celecoxib; Cyclooxygenase Inhibi | 2010 |
Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antioxidants; Aspartate Aminotransferases; | 2010 |
Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Celecoxib; | 2010 |
The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo.
Topics: Analgesics; Anemarrhena; Animals; Anti-Inflammatory Agents; Behavior, Animal; Capillary Permeability | 2010 |
Electroacupuncture versus celecoxib for neuropathic pain in rat SNL model.
Topics: Acupuncture Points; Analgesics; Animals; Celecoxib; Cyclooxygenase 2; Disease Models, Animal; Electr | 2010 |
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
Topics: Animals; Blotting, Western; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dendritic Cell | 2010 |
Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium.
Topics: Angiogenic Proteins; Animals; Apoptosis; Blood Pressure; Celecoxib; Collateral Circulation; Coronary | 2010 |
COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2010 |
Design, synthesis, and biological evaluation of 1,5-diaryl-1,2,4-triazole derivatives as selective cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitor | 2010 |
Gait analysis and pain response of two rodent models of osteoarthritis.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Gait; Male; Neuropeptides; | 2011 |
Anticonvulsant effect of celecoxib on pentylenetetrazole-induced convulsion: Modulation by NO pathway.
Topics: Animals; Anticonvulsants; Arginine; Celecoxib; Disease Models, Animal; Dose-Response Relationship, D | 2010 |
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 In | 2011 |
Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Barrett Esophagus; CDX2 Transcription Factor; Celeco | 2011 |
IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Enzyme-Linked Immunosorbent A | 2011 |
Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity.
Topics: Acetaminophen; Adaptive Immunity; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclo | 2011 |
Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD.
Topics: Adult; Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diseas | 2011 |
Pharmacokinetics of a combination of Δ9-tetrahydro-cannabinol and celecoxib in a porcine model of hemorrhagic shock.
Topics: Analgesics, Non-Narcotic; Animals; Blood Volume; Cardiac Output; Celecoxib; Chromatography, Liquid; | 2011 |
Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Celecoxib; Cyclooxygenase 2 Inhibito | 2010 |
Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model.
Topics: Animals; Cardiomyopathy, Dilated; Celecoxib; Disease Models, Animal; Dose-Response Relationship, Dru | 2011 |
Chemoprevention: First line of defence.
Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I | 2011 |
Inhibition of cyclooxygenase-2 modulates phenotypic switching of vascular smooth muscle cells during increased aortic blood flow.
Topics: Administration, Oral; Animals; Aorta; Arteriovenous Fistula; Celecoxib; Cyclooxygenase 2; Cyclooxyge | 2012 |
The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Chondrocytes; Col | 2012 |
The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis.
Topics: Analysis of Variance; Animals; Antigens, CD34; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygen | 2011 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Ster | 2011 |
Association of stem-like cells in gender-specific chemoprevention against intestinal neoplasia in MIN mouse.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemoprevention; Disease Models, Animal | 2011 |
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.
Topics: Analysis of Variance; Animals; Blotting, Western; Breast Neoplasms; Carcinoma, Ductal; Celecoxib; Ce | 2011 |
Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Blood Urea Nitrogen; Body Weight; Celecoxib; Ci | 2011 |
Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?
Topics: Animals; Celecoxib; Dialysis Solutions; Disease Models, Animal; Enalapril; Female; Humans; Male; Mic | 2012 |
Prostaglandin E(2) potentiates methylmalonate-induced seizures.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Electrodes, I | 2012 |
[Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Celecoxib; Cl | 2012 |
Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Appendiceal Neoplasms; Celecoxib; Colonic N | 2012 |
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Co | 2012 |
Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Celecoxib; Cell Cycle Checkpoints; Cell P | 2012 |
Inducible cyclooxygenase expression mediating hypoxia/reoxygenation-induced pulmonary vasoconstriction is attenuated by a cyclooxygenase inhibitor in rats.
Topics: Animals; Biomarkers; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disea | 2012 |
Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte.
Topics: Animals; Apoptosis; Cartilage, Articular; Celecoxib; Chondrocytes; Collagen Type II; Cyclooxygenase | 2012 |
[An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, | 2012 |
Cell intrinsic role of COX-2 in pancreatic cancer development.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Membrane; Cyclooxygenase 2; Disease Models, A | 2012 |
Celecoxib delays cognitive decline in an animal model of neurodegeneration.
Topics: Analysis of Variance; Animals; Celecoxib; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cytokine | 2012 |
Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype.
Topics: Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Aortic Rupture; Biomarkers; C | 2012 |
Pharmacological modulation of brain activity in a preclinical model of osteoarthritis.
Topics: Action Potentials; Animals; Brain; Celecoxib; Disease Models, Animal; Humans; Male; Nerve Net; Osteo | 2013 |
Cyclooxygenase-2 inhibition for the prevention of subglottic stenosis.
Topics: Animals; Celecoxib; Cicatrix; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Int | 2012 |
Vascular KCNQ (Kv7) potassium channels as common signaling intermediates and therapeutic targets in cerebral vasospasm.
Topics: Animals; Anthracenes; Arginine Vasopressin; Basilar Artery; Carbamates; Celecoxib; Disease Models, A | 2013 |
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.
Topics: Animals; Apoptosis; Celecoxib; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Cycloo | 2013 |
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenoma; Animals; Carcinogens; Carcinoma, Squamous Cell; Celecoxib | 2002 |
The effect of cyclooxygenase-2 inhibitors on spinal fusion.
Topics: Administration, Oral; Animals; Biopsy, Needle; Celecoxib; Confidence Intervals; Cyclooxygenase Inhib | 2002 |
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2002 |
Cancer "photo-chemoprevention" with pulsed dye laser and celecoxib.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Combined Modality Therapy; Disease Mo | 2003 |
Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice.
Topics: Animals; Celecoxib; Colitis; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Disease Models, Animal | 2003 |
Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer.
Topics: Administration, Topical; Animals; Celecoxib; Cell Division; Cyclooxygenase 2; Dinoprostone; Disease | 2003 |
Indomethacin and celecoxib improve tendon healing in rats.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Sectional S | 2003 |
Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2003 |
Role of cyclooxygenase enzymes in a murine model of experimental cholera.
Topics: Aldehydes; Animals; Celecoxib; Cholera; Cholera Toxin; Cyclooxygenase 1; Cyclooxygenase 2; Disease M | 2003 |
Pharmacological characterisation of a rat model of incisional pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Disease Model | 2004 |
The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
Topics: Animals; Biopsy, Needle; Blotting, Western; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, An | 2003 |
Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat.
Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2004 |
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.
Topics: Animals; Antineoplastic Agents; Carcinoma; Celecoxib; Colonic Neoplasms; Combined Modality Therapy; | 2004 |
Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
Topics: Acetamides; Animals; Celecoxib; Chlorpromazine; Coenzymes; Cyclooxygenase Inhibitors; Disease Models | 2004 |
Lipopolysaccharide-induced paw edema model for detection of cytokine modulating anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cells, Cultured; Disease M | 2004 |
Pharmacological characterisation of the rat brachial plexus avulsion model of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Analysis of Variance; Animals; Brachial Plexus; Brachial Plexus Neurop | 2004 |
Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats.
Topics: Animals; Celecoxib; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 2004 |
Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, A | 2004 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonat | 2004 |
Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Carrier Proteins; Cele | 2004 |
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxy | 2004 |
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Celecoxib; Cell Division; Cyclooxy | 2004 |
Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Western; Cele | 2004 |
Vioxx withdrawal alarms cancer prevention researchers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cyc | 2004 |
Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid.
Topics: Animals; Celecoxib; Colitis; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Inflam | 2004 |
Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
Topics: 4-Nitroquinoline-1-oxide; Animals; Apoptosis; Blotting, Western; Carcinogens; Carcinoma, Squamous Ce | 2005 |
Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Disease Mode | 2005 |
Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Carcinoma, Squamous Cell; Celecoxib; Ce | 2005 |
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carcinogen | 2005 |
Development and pharmacological characterization of a rat model of osteoarthritis pain.
Topics: Alkylating Agents; Analgesics, Opioid; Animals; Celecoxib; Cyclooxygenase Inhibitors; Disease Models | 2005 |
Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Dinoprost; D | 2005 |
Inhibition of cyclooxygenase 2 synthesis suppresses Herpes simplex virus type 1 reactivation.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diseas | 2005 |
Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect.
Topics: Adenocarcinoma; Animals; Celecoxib; Cells, Cultured; Cyclooxygenase Inhibitors; Disease Models, Anim | 2005 |
Effect of LLLT Ga-Al-As (685 nm) on LPS-induced inflammation of the airway and lung in the rat.
Topics: Animals; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Celecoxib; Chemotaxis, Leukocyte; | 2005 |
Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib.
Topics: Animals; Biopsy, Needle; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Immunohistoch | 2005 |
[A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats].
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 | 2005 |
Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antigens, Polyomavirus Transforming; Celecoxib; Cell Line, Tumor; | 2005 |
Effects of the celecoxib on the acute necrotizing pancreatitis in rats.
Topics: Animals; Celecoxib; Ceruletide; Cyclooxygenase Inhibitors; Disease Models, Animal; Edema; Glycodeoxy | 2004 |
Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Celecoxib; Cell Growth Processes; Cyclooxygen | 2006 |
Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Cyclooxygenase 2; | 2006 |
An animal model of calcium oxalate urolithiasis based on a cyclooxygenase 2 selective inhibitor.
Topics: Animals; Calcium Oxalate; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Kidney Tub | 2005 |
Lipopolysaccharide induces cyclooxygenase-2 in intestinal epithelium via a noncanonical p38 MAPK pathway.
Topics: Animals; Animals, Newborn; Blotting, Western; Celecoxib; Cyclooxygenase 2; Disease Models, Animal; E | 2006 |
9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2.
Topics: Alitretinoin; Animals; Antineoplastic Agents; Carcinogens; Celecoxib; Cell Transformation, Neoplasti | 2006 |
Effect of celecoxib on experimental liver fibrosis in rat.
Topics: Animals; Biopsy, Needle; Celecoxib; Connective Tissue Growth Factor; Cyclooxygenase 2; Cyclooxygenas | 2006 |
Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Bosentan; Carrageenan; Celecoxib; Cold | 2006 |
Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Behavior, | 2006 |
Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Hippocampus; Male; Muscarinic | 2006 |
Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib.
Topics: Abdomen; Angiogenesis Inhibitors; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, A | 2006 |
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.
Topics: Adjuvants, Immunologic; Animals; Cancer Vaccines; Celecoxib; Cell Line, Tumor; Cyclooxygenase Inhibi | 2006 |
Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage.
Topics: Animals; Caspase 3; CD11b Antigen; Celecoxib; Cerebral Hemorrhage; Collagenases; Disease Models, Ani | 2007 |
Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model.
Topics: Animal Feed; Animals; Apoptosis; Burkitt Lymphoma; Celecoxib; Cell Line, Tumor; Central Nervous Syst | 2006 |
Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygen | 2007 |
Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biopsy, Needle; C | 2006 |
Effects of cyclooxygenase-2 inhibitor on glucagon-induced delayed gastric emptying and gastric dysrhythmia in dogs.
Topics: Animals; Blood Glucose; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dogs; Female | 2007 |
Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis.
Topics: Animals; Antigens, Bacterial; Aprepitant; Bacillus anthracis; Bacterial Toxins; Capillary Permeabili | 2007 |
MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Contrast Media; Cyc | 2007 |
Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bony Callus; Celecoxib; Cyclooxygenase 2 Inhibitor | 2007 |
Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils.
Topics: Animals; Biomarkers, Tumor; Biopsy, Needle; CDX2 Transcription Factor; Celecoxib; Disease Models, An | 2006 |
A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer.
Topics: Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Col | 2007 |
Role of oxidative stress in celecoxib-induced renal damage in wistar rats.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Catalase; Celecoxib; Creatinine; Cyclooxygenase Inhibi | 2007 |
Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats.
Topics: Animals; Cardiovascular Diseases; Celecoxib; Colitis, Ulcerative; Colon; Cyclooxygenase 1; Cyclooxyg | 2007 |
Antiinflammatory effects of a combined herbal preparation (RAH13) of Phellodendron amurense and Coptis chinensis in animal models of inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coptis; Dexamethasone; Disease Models, | 2007 |
The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats.
Topics: Animals; Celecoxib; Consciousness; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dise | 2007 |
Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression.
Topics: Animals; Behavior, Animal; Brain Chemistry; Celecoxib; Cyclooxygenase Inhibitors; Cytokines; Depress | 2007 |
Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
Topics: Animals; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Din | 2008 |
Pro-inflammatory effect in mice of CvL, a lectin from the marine sponge Cliona varians.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemotaxis, Leukocyte; Dexamethasone; D | 2008 |
Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer.
Topics: Adenocarcinoma; Animals; Carcinogens; Celecoxib; Cricetinae; Cyclooxygenase 2; Cyclooxygenase Inhibi | 2007 |
The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2008 |
The effects of COX-1 and COX-2 inhibitors on prostaglandin synthesis and the formation of heterotopic bone in a rat model.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2008 |
Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
Topics: Animals; Aspirin; Blood Pressure; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 In | 2008 |
Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus.
Topics: Administration, Oral; Animals; Antibodies, Antinuclear; Apoptosis; B-Lymphocytes; Celecoxib; Cycloox | 2007 |
Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade.
Topics: Animals; Arthritis; Astrocytes; Behavior, Animal; Celecoxib; Collagen; Cyclooxygenase Inhibitors; Di | 2007 |
The effects of prostaglandin inhibition on whole-body ischemia-reperfusion in swine.
Topics: Animals; Cardiopulmonary Resuscitation; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Disease | 2008 |
Prostaglandin inhibition and ischemia: where are the data?
Topics: Animals; Cardiopulmonary Resuscitation; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal | 2008 |
Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Animals; Brain; Celecoxib; Disease Mo | 2008 |
Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model.
Topics: Animals; Anticarcinogenic Agents; Breast; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; | 2008 |
Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice.
Topics: Anilides; Animals; Antipruritics; Behavior, Animal; Bradykinin Receptor Antagonists; Calcitonin Gene | 2008 |
Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury.
Topics: Amygdala; Animals; Brain Injuries; Celecoxib; Cerebral Cortex; Cyclooxygenase 2; Cyclooxygenase 2 In | 2000 |
[Gastrointestinal damage induced by celecoxib and rofecoxib in rats].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Disease Mode | 2000 |
Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis.
Topics: Animals; Blotting, Western; Celecoxib; Colitis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclo | 2000 |
Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Membrane Permeability; Cyclooxygen | 2000 |
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agent | 2000 |
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Squamous Cel | 2000 |
Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Dinoprostone; Disease | 2001 |
Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.
Topics: Acetylcholine; Animals; Arachidonic Acid; Aspirin; Benzofurans; Blood Flow Velocity; Celecoxib; Coro | 2001 |
A protective role for cyclooxygenase-2 in drug-induced liver injury in mice.
Topics: Acetaminophen; Animals; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2; Cycloox | 2001 |
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anim | 2002 |
A rat model of bone cancer pain.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Body Tempera | 2002 |
Protective effects of Celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cytokines; Disease Models, | 2002 |
Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model.
Topics: Animals; Biopsy, Needle; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; | 2002 |